JPWO2020212952A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020212952A5 JPWO2020212952A5 JP2021561958A JP2021561958A JPWO2020212952A5 JP WO2020212952 A5 JPWO2020212952 A5 JP WO2020212952A5 JP 2021561958 A JP2021561958 A JP 2021561958A JP 2021561958 A JP2021561958 A JP 2021561958A JP WO2020212952 A5 JPWO2020212952 A5 JP WO2020212952A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disorder
- crystalline psilocybin
- subject
- psilocybin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Description
上述のものは、本発明の例示説明であり、その限定として解釈されるべきでない。本発明は、その中に含まれる請求項の均等物と共に、以下の請求項によって定義される。
特定の実施形態では、例えば、以下が提供される：
（項目１）
うつ病の治療を必要とする対象におけるうつ病を治療する方法であって、前記対象に、有効量のサイロシビンまたはその活性代謝産物を投与することを含む、前記方法。
（項目２）
前記対象が、大うつ病性障害、非定型うつ病、双極性障害、緊張病性うつ病、医学的状態に起因するうつ病性障害、分娩後うつ病、月経前不快気分障害、または季節性情動障害を有する、項目１に記載の方法。
（項目３）
前記対象が、大うつ病性障害を有する、項目２に記載の方法。
（項目４）
前記対象が、双極性障害を有する、項目２に記載の方法。
（項目５）
前記対象が、双極性障害Ｉ型を有する、項目４に記載の方法。
（項目６）
前記対象が、双極性障害ＩＩ型を有する、項目４に記載の方法。
（項目７）
前記うつ病が、治療に対して抵抗性である、項目１～６のいずれか一項に記載の方法。
（項目８）
うつ病の少なくとも１つの兆候または症状が、低減される、項目１～７のいずれか一項に記載の方法。
（項目９）
前記うつ病の兆候または症状が、抑うつ気分、活動への関心の低下、体重減少もしくは増加、食欲の低下もしくは増加、不眠症もしくは過眠症、精神運動性激越もしくは遅延、疲労もしくはエネルギーの喪失、無価値感もしくは過度もしくは不適切な罪悪感、集中力の低下もしくは決断力の欠如、または自殺念慮もしくは行動である、項目８に記載の方法。
（項目１０）
前記うつ病の兆候または症状が、日記評価、臨床医もしくは介護士による評価、臨床評価スケールに従って、または機能的ＭＲＩによって測定される、項目９に記載の方法。
（項目１１）
前記臨床うつ病評価スケールが、簡易抑うつ症状尺度（ＱＩＤＳ）－１６スケール、ＱＩＤＳ－１６日常スケール、ハミルトンうつ病評価スケール、Ｂｅｃｋうつ病インベントリスケール、Ｍｏｎｔｇｏｍｅｒｙ－Ａｓｂｅｒｇうつ病評価スケール、臨床グローバル印象スケール、Ｚｕｎｇ自己評価うつ病スケール、Ｒａｓｋｉｎうつ病評価スケール、及び／またはヤングマニア評価スケールである、項目１０に記載の方法。
（項目１２）
前記うつ病の兆候または症状が、Ｓｐｉｅｌｂｅｒｇｅｒの特質及び不安インベントリ、全般性不安障害７項目スケール、Ｗａｒｗｉｃｋ－Ｅｄｉｎｂｕｒｇｈメンタルウェルビーイングスケール、Ｆｌｏｕｒｉｓｈｉｎｇスケール、Ｓｎａｉｔｈ Ｈａｍｉｌｔｏｎ快感消失喜びスケール、ライフオリエンテーションテスト、人生の意義質問票、ブリーフレジリエンススケール、非機能的態度スケール、４４項目のビッグファイブインベントリ、ピーターズ２１項目の妄想インベントリ、異常な自己経験の検査、考え込み型反応スケール、シロクマ抑制インベントリ、バレット衝動性スケール、簡易の体験的回避質問票、改変Ｔｅｌｌｅｇｅｎ没頭質問票、治療的関係を評価するためのスケール、信頼性／期待度質問票、自然とのつながりスケール、政治的展望質問票、社会的つながりスケール、Ｂｅｃｈ－Ｒａｆａｅｌｓｅｎマニア評価スケール、改訂されたＳａｎｔａ Ｃｌａｒａ簡潔な思いやりスケール、感謝の質問票、短い推奨度スケール、Ｒｏｓｅｎｂｅｒｇ自尊心スケール、精神的超越スケールの普遍性サブスケール、抗うつ剤の感情的な副作用に関するオックスフォード質問票、Ｌａｕｋｓ感情強度スケール、性機能障害質問票、女性の性機能の簡潔な指標、性認識質問票、Ｂａｒｎｅｓ Ａｋａｔｈｉｓｉａ評価スケール、作業生産性及び活動障害質問票、仕事及び社会的適応度スケール、つながり質問票、人格の標準評価、陽性及び陰性症候群スケール、マスタリーインサイトスケール、自己省察（Ｓｅｌｆ－Ｒｅｆｌｅｃｔｉｏｎ）及びインサイトスケール、心理学的インサイトスケール、形而上学的信念質問票、スピリチュアルバイパス（Ｓｐｉｒｉｔｕａｌ Ｂｙｐａｓｓｉｎｇ）スケール、有害な幼少期経験質問票、治療音楽体験質問票、設定質問票、音楽没頭スケール、サイケデリック予測因子（Ｐｓｙｃｈｅｄｅｌｉｃ Ｐｒｅｄｉｃｔｏｒ）スケール、降伏スケール、ＥｕｒｏＱＯＬ－５次元－３レベルスケール、コロンビア自殺重症度評価スケール、自殺念慮属性スケール、またはこれらの任意の組み合わせを使用して測定される、項目１０に記載の方法。
（項目１３）
前記機能的ＭＲＩが、扁桃体の血液酸素レベル依存性（ＢＯＬＤ）反応を測定する、項目１０に記載の方法。
（項目１４）
前記ＢＯＬＤ反応が、安静状態で、感情的な顔、及び／または快楽刺激としての音楽に応答して測定される、項目１３に記載の方法。
（項目１５）
うつ病の少なくとも１つの兆候または症状が、前記サイロシビンの投与から２４時間以内に緩和される、項目１～１４のいずれか一項に記載の方法。
（項目１６）
うつ病の少なくとも１つの症状が、前記サイロシビンの投与から１週間以内に緩和される、項目１～１４のいずれか一項に記載の方法。
（項目１７）
うつ病の少なくとも１つの症状が、前記サイロシビンの投与後、少なくとも１か月間緩和される、項目１～１４のいずれか一項に記載の方法。
（項目１８）
前記うつ病の少なくとも１つの症状が、前記サイロシビンの投与後、少なくとも３か月間緩和される、項目１～１４のいずれか一項に記載の方法。
（項目１９）
前記うつ病の少なくとも１つの症状が、前記サイロシビンの投与後、少なくとも１２か月間緩和される、項目１～１４のいずれか一項に記載の方法。
（項目２０）
前記サイロシビンの投与後、前記うつ病の兆候または症状を低減するための他の治療は、前記対象に施されない、項目１～１９のいずれか一項に記載の方法。
（項目２１）
前記対象に、前記うつ病の兆候または症状を低減するための少なくとも１つの追加の治療剤を投与することをさらに含む、項目１～１９のいずれか一項に記載の方法。
（項目２２）
前記少なくとも１つの追加の治療剤が、選択的セロトニン再取り込み阻害剤、セロトニン及びノルエピネフリン再取り込み阻害剤、三環式抗うつ剤、四環式抗うつ剤、ドーパミン再取り込み阻害剤、５－ＨＴ
１Ａ
受容体アンタゴニスト、５－ＨＴ
２
受容体アンタゴニスト、５－ＨＴ
３
受容体アンタゴニスト、モノアミン酸化酵素阻害剤、またはノルアドレナリン作動性アンタゴニストである、項目２１に記載の方法。
（項目２３）
前記少なくとも１つの追加の治療剤が、サイロシビンの投与前に投与される、項目２１または２２に記載の方法。
（項目２４）
前記少なくとも１つの追加の治療剤が、サイロシビンの投与後に投与される、項目２１または２２に記載の方法。
（項目２５）
前記少なくとも１つの追加の治療剤が、前記サイロシビンと同じ日に投与される、項目２１または２２に記載の方法。
（項目２６）
前記対象が、以前にサイロシビンに曝露されていない、項目１～２５のいずれか一項に記載の方法。
（項目２７）
前記対象が、以前にサイロシビンに曝露されている、項目１～２５のいずれか一項に記載の方法。
（項目２８）
前記対象が、さらなる併存疾患または障害を有する、項目１～２７のいずれか一項に記載の方法。
（項目２９）
前記対象が、不安障害、強迫性障害、アルコール依存症、人格障害、心血管疾患、神経疾患、またはがんを有する、項目２８に記載の方法。
（項目３０）
前記神経疾患が、認知症、アルツハイマー病、またはパーキンソン病である、項目２９に記載の方法。
（項目３１）
前記対象におけるうつ病の少なくとも１つの兆候または症状の低減が、前記対象における１つ以上の併存疾患または障害を治療または予防する、項目２８～３０のいずれか一項に記載の方法。
（項目３２）
前記対象が、哺乳動物である、項目１～３１のいずれか一項に記載の方法。
（項目３３）
前記対象が、ヒトである、項目３２に記載の方法。
（項目３４）
前記サイロシビンが、治療有効量の多形体Ａの形態での高純度結晶性サイロシビンを含む剤形で投与され、前記結晶性サイロシビンが、少なくとも９０重量％の多形体Ａを含む、項目１～３３のいずれかに記載の方法。
（項目３５）
前記結晶性サイロシビンが、少なくとも９５重量％の多形体Ａを含む、項目３４に記載の方法。
（項目３６）
前記結晶性サイロシビンが、ＨＰＬＣによって９７％超の化学純度を有し、１％超の単一の不純物を有しない、項目３４または３５に記載の方法。
（項目３７）
前記サイロシビンが、治療有効量の多形体Ａの形態での高純度結晶性サイロシビンを含む剤形で投与され、前記結晶性サイロシビンが、ＨＰＬＣによって９７％超の化学純度を有し、１％超の単一の不純物を有しない、項目１～３３のいずれか一項に記載の方法。
（項目３８）
前記高純度結晶性サイロシビンが、少なくとも９０重量％の多形体Ａを含む、項目３７に記載の方法。
（項目３９）
前記高純度結晶性サイロシビンが、少なくとも９５重量％の多形体Ａを含む、項目３８に記載の方法。
（項目４０）
前記高純度結晶性サイロシビンが、（ｉ）０．５ｗ／ｗ％未満の水含有量、または（ｉｉ）２５℃～２００℃のＴＧＡサーモグラムにおける０．５ｗ／ｗ％未満の減量のいずれかを有することをさらに特徴とする、項目３４～３９のいずれか一項に記載の方法。
（項目４１）
前記高純度結晶性サイロシビンが、１４５℃～１５５℃の第１の開始温度及び２０５℃～２２０℃の第２の開始温度を有するＤＳＣサーモグラムにおける吸熱事象をさらに特徴とする、項目３４～４０のいずれか一項に記載の方法。
（項目４２）
前記高純度結晶性サイロシビンが、以下のうちの１つ以上をさらに特徴とする、項目３４～４１のいずれか一項に記載の方法：（ａ）２ｗ／ｗ％以下の乾燥減量、（ｂ）０．５ｗ／ｗ％以下の発火における残留物、（ｃ）ＨＰＬＣによって測定される９５～１０３重量％のアッセイ（乾燥ベース）、（ｄ）ＨＲＧＣによって測定される、３０００ｐｐｍ以下のメタノール、５０００ｐｐｍのエタノール、７２０ｐｐｍのＴＨＦ、及び８９０ｐｐｍのトルエンの残留溶媒含有量、（ｅ）
３１
Ｐ ＮＭＲによって測定される、１ｗ／ｗ％以下のリン酸含有量、ならびに（ｆ）（ｉ）１．５ｐｐｍ以下のＣｄ、（ｉｉ）１．５ｐｐｍ以下のＰｂ、（ｉｉｉ）４．５ｐｐｍ以下のＡｓ、（ｉｖ）９．０ｐｐｍ以下のＨｇ、（ｖ）１５ｐｐｍ以下のＣｏ、（ｖｉ）３０ｐｐｍ以下のＶ、（ｖｉｉ）６０ｐｐｍ以下のＮｉ、（ｖｉｉｉ）１６５ｐｐｍ以下のＬｉ、及び（ｉｘ）３０ｐｐｍ以下のＰｄの誘導結合プラズマ質量分析（ＩＣＰ－ＭＳ）元素分析。
（項目４３）
前記高純度結晶性サイロシビンが、０．５％超の単一の不純物を有しない、項目３４～４２のいずれか一項に記載の方法。
（項目４４）
前記剤形が、約５～４０ｍｇの前記高純度結晶性サイロシビンをさらに含む、項目３４～４３のいずれかに記載の方法。
（項目４５）
前記剤形が、５ｍｇの高純度結晶性サイロシビンを含む、項目４４に記載の方法。
（項目４６）
前記剤形が、約１０ｍｇの高純度結晶性サイロシビンを含む、項目４４に記載の方法。
（項目４７）
前記剤形が、約３５ｍｇの高純度結晶性サイロシビンを含む、項目４４に記載の方法。
（項目４８）
前記剤形が、ケイ化微結晶セルロースを含む、項目３４～４７のいずれか一項に記載の方法。
（項目４９）
前記ケイ化微結晶セルロースが、約４５～１５０ミクロンの粒径範囲を有する、項目４８に記載の方法。
（項目５０）
２つのケイ化微結晶セルロースバリアントの混合物をさらに含み、前記第１のバリアントが、約４５～８０ミクロンの粒径を有し、前記第２のバリアントが、約９０～１５０ミクロンの粒径を有する、項目３４～４９のいずれか一項に記載の方法。
（項目５１）
前記微結晶セルロースの約３０％以下が、前記約４５～８０ミクロンの粒径を有する第１のバリアントであり、前記微結晶セルロースの約７０％以上が、前記約９０～１５０ミクロンの粒径を有する第２のバリアントである、項目５０に記載の方法。
（項目５２）
前記微結晶セルロースの約２０％以下が、前記約４５～８０ミクロンの粒径を有する第１のバリアントであり、前記微結晶セルロースの約８０％以上が、前記約９０～１５０ミクロンの粒径を有する第２のバリアントである、項目５０に記載の方法。
（項目５３）
前記微結晶セルロースの約１５％以下が、前記約４５～８０ミクロンの粒径を有する第１のバリアントであり、前記微結晶セルロースの約８５％以上が、前記約９０～１５０ミクロンの粒径を有する第２のバリアントである、項目５０に記載の方法。
（項目５４）
前記剤形が、多形体Ａの形態での５ｍｇの結晶性サイロシビン、１２．５ｍｇのＳＭＣＣ ５０、７９．５ｍｇのＳＭＣＣ ９０、１ｍｇのグリコール酸ナトリウムデンプン、１ｍｇのコロイド状二酸化ケイ素、及び１ｍｇのステアリルフマル酸ナトリウムを含む、項目５３に記載の方法。
（項目５５）
前記剤形が、多形体Ａの形態での１ｍｇの結晶性サイロシビン、２０．５ｍｇのＳＭＣＣ ５０、７５．５ｍｇのＳＭＣＣ ９０、１ｍｇのグリコール酸ナトリウムデンプン、１ｍｇのコロイド状二酸化ケイ素、及び１ｍｇのステアリルフマル酸ナトリウムを含む、項目５３に記載の方法。
（項目５６）
前記剤形が、経口剤形である、項目３４～５５のいずれか一項に記載の方法。
（項目５７）
前記剤形が、カプセルである、項目５６に記載の方法。
（項目５８）
前記剤形が、錠剤である、項目５６に記載の方法。
（項目５９）
少なくとも１つの用量のサイロシビンが、前記対象に投与される、項目１～５８のいずれか一項に記載の方法。
（項目６０）
前記少なくとも１つの用量のサイロシビンが、約０．１ｍｇ～約１００ｍｇの範囲内である、項目５９に記載の方法。
（項目６１）
サイロシビンの前記用量が、約１ｍｇである、項目６０に記載の方法。
（項目６２）
サイロシビンの前記用量が、約１０ｍｇである、項目６０に記載の方法。
（項目６３）
サイロシビンの前記用量が、約２５ｍｇである、項目６０に記載の方法。
（項目６４）
１回を超えるサイロシビンの用量が、前記対象に投与される、項目１～５８のいずれか一項に記載の方法。
（項目６５）
少なくとも２回の用量のサイロシビンが、前記対象に投与される、項目６５に記載の方法。
（項目６６）
前記サイロシビンが、１日１回投与される、項目６４～６５のいずれか一項に記載の方法。
（項目６７）
前記サイロシビンが、１週間に少なくとも１回投与される、項目６４～６５のいずれか一項に記載の方法。
（項目６８）
前記サイロシビンが、１週間に少なくとも２回投与される、項目６４～６５のいずれか一項に記載の方法。
（項目６９）
前記サイロシビンが、１か月に少なくとも１回投与される、項目６４～６５のいずれか一項に記載の方法。
（項目７０）
前記サイロシビンが、１か月に少なくとも２回投与される、項目６４～６５のいずれか一項に記載の方法。
（項目７１）
前記サイロシビンが、３か月毎に少なくとも１回投与される、項目６４～６５のいずれか一項に記載の方法。
（項目７２）
前記サイロシビンが、６か月毎に少なくとも１回投与される、項目６４～６５のいずれか一項に記載の方法。
（項目７３）
前記サイロシビンが、１２か月毎に少なくとも１回投与される、項目６４～６５のいずれか一項に記載の方法。
（項目７４）
投与されるサイロシビンの各用量が、約０．１ｍｇ～約１００ｍｇの範囲内である、項目６４～７３のいずれか一項に記載の方法。
（項目７５）
投与されるサイロシビンの各用量が、約１ｍｇである、項目７４に記載の方法。
（項目７６）
投与されるサイロシビンの各用量が、約１０ｍｇである、項目７４に記載の方法。
（項目７７）
投与されるサイロシビンの各用量が、約２５ｍｇである、項目７４に記載の方法。
（項目７８）
前記サイロシビンが、経口、静脈内、筋肉内、非経口、局所、吸入、直腸、経粘膜、鼻腔内、頬、膣、くも膜下腔内、眼内、経皮、子宮内、リンパ内の経路のうちの１つによって、または直接組織もしくは臓器注射によって投与される、項目５９～７７のいずれか一項に記載の方法。
（項目７９）
前記サイロシビンが、経口投与される、項目７８に記載の方法。
（項目８０）
前記対象が、前記サイロシビンの投与前、少なくとも１つの心理的支援セッションに参加する、項目１～７９のいずれか一項に記載の方法。
（項目８１）
前記対象が、前記サイロシビンの投与前、少なくとも３つの心理的支援セッションに参加する、項目８０に記載の方法。
（項目８２）
少なくとも１つの治療的意図が、前記心理的支援セッション中に話し合われる、項目８０～８１のいずれか一項に記載の方法。
（項目８３）
自己主導型問診及び経験的処理が、前記心理的支援セッション中に実施される、項目８０～８２のいずれか一項に記載の方法。
（項目８４）
前記対象が、前記サイロシビンの投与後、少なくとも１つの心理的支援セッションに参加する、項目８０～８３のいずれか一項に記載の方法。
（項目８５）
前記対象が、前記サイロシビンの投与後、少なくとも３つの心理的支援セッションに参加する、項目８４に記載の方法。
（項目８６）
前記サイロシビンが、実質的に非臨床的な外観を有する部屋において前記対象に投与される、項目８０～８５のいずれか一項に記載の方法。
（項目８７）
前記部屋が、柔らかい家具を備える、項目８６に記載の方法。
（項目８８）
前記部屋が、落ち着いた色を使用して装飾される、項目８６に記載の方法。
（項目８９）
前記部屋が、高解像度の音響システムを備える、項目８６に記載の方法。
（項目９０）
前記部屋が、ベッドまたはソファを備える、項目８６～８９のいずれか一項に記載の方法。
（項目９１）
前記対象が、前記サイロシビンの投与後、約４～８時間、またはそのかなりの割合でベッドまたはソファに横たわる、項目９０に記載の方法。
（項目９２）
前記対象が、前記サイロシビンの投与後、約４～８時間、またはそのかなりの割合で音楽を聴く、項目８６～９１のいずれか一項に記載の方法。
（項目９３）
前記対象が、前記サイロシビンの投与後、約４～８時間、またはそのかなりの割合でアイマスクを装着する、項目８６～９２のいずれか一項に記載の方法。
（項目９４）
療法士が、前記サイロシビンの投与後、約４～８時間、前記対象に心理的支援を提供する、項目８７～９３のいずれか一項に記載の方法。
（項目９５）
前記療法士が、前記対象を落ち着かせる及び／または前記対象の注意を集中させるために誘導イメージ療法及び／または呼吸運動を使用する、項目９４に記載の方法。
（項目９６）
前記療法士が、前記対象との安心させる物理的接触を提供する、項目９４に記載の方法。
（項目９７）
前記療法士が、前記対象の手、腕、または肩に触れる、項目９６に記載の方法。
（項目９８）
前記療法士が、前記対象に自己主導型問診及び経験的処理を実行することを奨励する、項目９４に記載の方法。
（項目９９）
前記療法士が、前記対象に少なくとも１つの治療的意図を思い出させる、項目９４に記載の方法。
（項目１００）
前記療法士が、以下のうちの１つ以上を行うように前記対象をカウンセリングする、項目９４に記載の方法：（１）不安の感情を受け入れること、（２）経験を自然に展開させること、（３）経験に対する心理的抵抗を避けること、（４）リラックスすること、及び／または（５）前記対象自身の精神空間を探求すること。
（項目１０１）
前記療法士が、前記対象との会話を開始しない、項目９４に記載の方法。
（項目１０２）
前記療法士が、前記対象が会話を開始する場合、前記対象に応答する、項目９４に記載の方法。
（項目１０３）
前記心理的支援が、前記対象に遠隔的に提供される、項目８０～１０２のいずれか一項に記載の方法。
（項目１０４）
前記心理的支援が、デジタルまたは電子システムを介して提供される、項目１０３に記載の方法。
（項目１０５）
前記デジタルまたは前記電子システムが、携帯電話アプリである、項目１０４に記載の方法。
（項目１０６）
前記デジタルまたは前記電子システムが、ウェブサイトである、項目１０５に記載の方法。
（項目１０７）
本特許請求の範囲に記載の方法。
（項目１０８）
本特許請求の範囲に記載の製剤。
（項目１０９）
本特許請求の範囲に記載の結晶性サイロシビン。
（項目１１０）
本特許請求の範囲に記載のように本特許請求の範囲に記載の結晶性サイロシビンを含む、薬学的剤形。
（項目１１１）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、以下の疾患、障害、または状態のうちの少なくとも１つを有する、前記方法：重篤気分調節障害、大うつ病性障害（ＭＤＤ）、治療抵抗性うつ病、持続性抑うつ障害（気分変調症）、月経前不快気分障害、物質／薬剤誘発性抑うつ障害、分娩後うつ病、または別の医学的状態に起因する抑うつ障害、分離不安障害、選択的無言症、特定恐怖症、社会不安障害（社会恐怖症）、パニック障害、パニック発作、広場恐怖症、全般性不安障害、物質－薬剤誘発性不安障害、別の病態に起因する不安障害、身体症状障害、病気不安障害（心気症）、転換性障害（機能性神経症状障害）、虚偽性障害、心的外傷後ストレス障害（ＰＴＳＤ）、適応障害、急性苦痛障害、強迫性障害、身体醜形障害、ホーディング障害、抜毛癖（抜毛）障害、擦りむき（皮膚むしり）障害、物質／薬物誘発性強迫性及び関連障害、別の病態に起因する強迫性及び関連障害、物質関連障害、アルコール関連障害、***関連障害、幻覚剤関連障害、吸入剤関連障害、コカイン関連の障害、オピオイド関連障害、鎮静剤関連、睡眠剤関連、または抗不安剤関連障害、刺激剤関連障害、タバコ関連障害、非物質関連障害（ギャンブルまたはゲーム障害）、片頭痛、慢性群発性頭痛などの群発性頭痛、周期的嘔吐、緊張型頭痛、不全失語症、異食症、神経性拒食症、神経性過食症、過食性障害、反抗的行為障害、間欠性爆発性障害、行為障害、***的人格障害、精神病質、放火癖、または窃盗癖。
（項目１１２）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、以下の疾患、障害、または状態のうちの少なくとも１つを有する、前記方法：アルツハイマー病、レビー小体、外傷性脳損傷、プリオン病、ＨＩＶ感染症、パーキンソン病、またはハンチントン病に起因する神経認知障害、脳震盪、慢性外傷性脳症（ＣＴＥ）、言語障害、発話障害（音声障害）、小児期発症性流動性障害（吃音）、社会的（実用的）コミュニケーション障害、トゥレット障害、持続性（慢性）運動または声帯チック障害、既知の生理学的状態に起因する健忘障害、一過性脳虚血発作、脳梗塞、脳出血、進行性多核眼筋麻痺、または逆行性健忘。
（項目１１３）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、以下の疾患、障害、または状態のうちの少なくとも１つを有する、前記方法：自閉症スペクトラム障害または***的人格障害。
（項目１１４）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、以下の疾患、障害、または状態のうちの少なくとも１つを有する、前記方法：注意欠陥／多動性障害、その他の特定の注意欠陥／多動性障害、または特定されていない注意欠陥／多動性障害。
（項目１１５）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、以下の疾患、障害、または状態のうちの少なくとも１つを有する、前記方法：統合失調性（人格）障害、妄想性障害、統合失調症、または統合失調性感情障害。
（項目１１６）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、以下の疾患、障害、または状態のうちの少なくとも１つを有する、前記方法：女性の性的興味／性的興奮障害、男性の性的欲求低下障害、または過度の性的衝動。
（項目１１７）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、以下の疾患、障害、または状態のうちの少なくとも１つを有する、前記方法：双極性障害Ｉ型、双極性障害ＩＩ型、または気分循環性障害。
（項目１１８）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、以下の疾患、障害、または状態のうちの少なくとも１つを有する、前記方法：不眠障害、過眠障害、ナルコレプシー、または原発性中枢性睡眠時無呼吸症、のうちの少なくとも１つを有する、前記方法。
（項目１１９）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、以下の疾患、障害、または状態のうちの少なくとも１つを有する、前記方法：統合失調症性人格障害、統合失調症型人格障害、***的人格障害、境界性人格障害、または強迫性人格障害。
（項目１２０）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、以下の疾患、障害、または状態のうちの少なくとも１つを有する、前記方法：加齢関連聴力損失または耳鳴。
（項目１２１）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、以下の疾患、障害、または状態のうちの少なくとも１つを有する、前記方法：多発性硬化症、脳神経障害、視神経脊髄炎、ベル麻痺、ギランバレー症候群、中枢神経系の脱髄性疾患、または慢性炎症性脱髄性多発神経炎。
（項目１２２）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、疼痛に苦しんでいる、前記方法。
（項目１２３）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、以下の疾患、障害、または状態のうちの少なくとも１つを有する、前記方法：脊髄症、外傷性脳損傷、知的障害、躁病、神経変性、性的倒錯障害、自殺行動障害、非自殺性自傷行為障害、持続性複雑死障害、胃腸管関連疾患、てんかん、鎌状赤血球病、ロックイン症候群、レストレスレッグス症候群、脳卒中、または筋萎縮性側索硬化症（ＡＬＳ）。
（項目１２４）
対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、投与後、前記対象が、認知の改善を示す、前記方法。
（項目１２５）
前記認知の改善が、注意、エピソード記憶、作業記憶、空間記憶、社会的認知、実行機能、及び／または認知の柔軟性の改善である、項目１２４に記載の方法。
（項目１２６）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、治療抵抗性うつ病（ＴＲＤ）を有する、前記方法。
（項目１２７）
治療を必要とする対象を治療する方法であって、前記対象に、治療有効用量のサイロシビンを投与することを含み、前記対象が、大うつ病性障害（ＭＤＤ）を有する、前記方法。
（項目１２８）
前記対象が、哺乳動物である、項目１１１～１２７のいずれか一項に記載の方法。
（項目１２９）
前記対象が、ヒトである、項目１８に記載の方法。
（項目１３０）
前記サイロシビンが、治療有効量の多形体Ａの形態での高純度結晶性サイロシビンを含む剤形で投与され、前記結晶性サイロシビンが、少なくとも９０重量％の多形体Ａを含む、項目１１１～１２９のいずれかに記載の方法。
（項目１３１）
前記結晶性サイロシビンが、少なくとも９５重量％の多形体Ａを含む、項目１３０に記載の方法。
（項目１３２）
前記結晶性サイロシビンが、ＨＰＬＣによって９７％超の化学純度を有し、１％超の単一の不純物を有しない、項目１３０または１３１に記載の方法。
（項目１３３）
前記サイロシビンが、治療有効量の多形体Ａの形態での高純度結晶性サイロシビンを含む剤形で投与され、前記結晶性サイロシビンが、ＨＰＬＣによって９７％超の化学純度を有し、１％超の単一の不純物を有しない、項目１１１～１３２のいずれかに記載の方法。
（項目１３４）
２つのケイ化微結晶セルロースバリアントの混合物をさらに含み、前記第１のバリアントが、約４５～８０ミクロンの粒径を有し、前記第２のバリアントが、約９０～１５０ミクロンの粒径を有する、項目１３０～１３３のいずれかに記載の方法。
（項目１３５）
前記微結晶セルロースの約３０％以下が、前記約４５～８０ミクロンの粒径を有する第１のバリアントであり、前記微結晶セルロースの約７０％以上が、前記約９０～１５０ミクロンの粒径を有する第２のバリアントである、項目２４に記載の方法。
（項目１３６）
前記剤形が、経口剤形である、項目１３０～１３５のいずれか一項に記載の方法。
（項目１３７）
前記剤形が、カプセルである、項目１３６に記載の方法。
（項目１３８）
前記剤形が、錠剤である、項目１３６に記載の方法。
（項目１３９）
少なくとも１つの用量のサイロシビンが、前記対象に投与される、項目１１１～１３８のいずれか一項に記載の方法。
（項目１４０）
前記少なくとも１つの用量のサイロシビンが、約０．１ｍｇ～約１００ｍｇの範囲内である、項目１３９に記載の方法。
（項目１４１）
サイロシビンの前記用量が、約２５ｍｇである、項目１４０に記載の方法。
（項目１４２）
前記対象が、前記サイロシビンの投与前、少なくとも１つの心理的支援セッションに参加する、項目１１１～１４１のいずれか一項に記載の方法。
（項目１４３）
前記対象が、前記サイロシビンの投与後、少なくとも１つの心理的支援セッションに参加する、項目１４２に記載の方法。
（項目１４４）
療法士が、前記サイロシビンの投与後、約４～８時間、前記対象に心理的支援を提供する、項目１４２または１４３に記載の方法。
（項目１４５）
治療有効量の多形体Ａの形態での高純度結晶性サイロシビンを含む剤形であって、前記結晶性サイロシビンが、少なくとも９０重量％の多形体Ａを含み、２つのケイ化微結晶セルロースバリアントの混合物をさらに含み、前記第１のバリアントが、約４５～８０ミクロンの粒径（ＳＭＣＣ ５０）を有し、前記第２のバリアントが、約９０～１５０ミクロンの粒径（ＳＭＣＣ ９０）を有し、ＳＭＣＣ ５０対ＳＭＣＣ ９０の比率が、１：５～１：８の重量％である、前記剤形。
（項目１４６）
崩壊剤、流動促進剤、または滑沢剤をさらに含む、項目１４５に記載の剤形。
（項目１４７）
崩壊剤を含み、前記崩壊剤が、３％未満（重量％）、２％未満、または１％以下のデンプングリコール酸ナトリウムである、項目１４７に記載の剤形。
（項目１４８）
ＳＭＣＣ ５０対ＳＭＣＣ ９０の比率が、１：５～１：７、１：６～１：７、１：６～１：８、１．７～１．８、１：６、１：６．１、１：６．２、１：６．３、１：６．４、１：６．５、１：６．６、１．６．７、１：６．８、１．６．９、または１：７である、項目１４５～１４７のいずれか一項に記載の剤形。
（項目１４９）
５～４０ｍｇのサイロシビンを含む、項目１４５～１４７のいずれか一項に記載の剤形。
（項目１５０）
５ｍｇのサイロシビン、ＳＭＣＣ ５０及びＳＭＣＣ ９０（ＳＭＣＣ ５０対ＳＭＣＣ ９０の比率が、１：６．４である）、ならびに約０．５％～１．０％のデンプングリコール酸ナトリウムを含む、項目１４５に記載の剤形。
（項目１５１）
５ｍｇのサイロシビン、ＳＭＣＣ ５０及びＳＭＣＣ ９０（ＳＭＣＣ ５０対ＳＭＣＣ ９０の比率が、１：６．４である）、ならびに約０．５％のデンプングリコール酸ナトリウムを含む、項目１４５に記載の剤形。
（項目１５２）
１０ｍｇのサイロシビン、ＳＭＣＣ ５０及びＳＭＣＣ ９０（ＳＭＣＣ ５０対ＳＭＣＣ ９０の比率が、１：６．４である）、ならびに約１％のデンプングリコール酸ナトリウムを含む、項目１４５に記載の剤形。
（項目１５３）
１０ｍｇのサイロシビン、ＳＭＣＣ ５０及びＳＭＣＣ ９０（ＳＭＣＣ ５０対ＳＭＣＣ ９０の比率が、１：６．４である）、ならびに約０．５％～１．０％のデンプングリコール酸ナトリウムを含む、項目１４５に記載の剤形。
（項目１５４）
１０ｍｇのサイロシビン、ＳＭＣＣ ５０及びＳＭＣＣ ９０（ＳＭＣＣ ５０対ＳＭＣＣ ９０の比率が、１：６．４である）、ならびに約０．５％のデンプングリコール酸ナトリウムを含む、項目１４５に記載の剤形。
（項目１５５）
２５ｍｇのサイロシビン、ＳＭＣＣ ５０及びＳＭＣＣ ９０（ＳＭＣＣ ５０対ＳＭＣＣ ９０の比率が、１：６．４である）、ならびに約１％のデンプングリコール酸ナトリウムを含む、項目１４５に記載の剤形。
（項目１５６）
２５ｍｇのサイロシビン、ＳＭＣＣ ５０及びＳＭＣＣ ９０（ＳＭＣＣ ５０対ＳＭＣＣ ９０の比率が、１：６．４である）、ならびに約０．５％～１．０％のデンプングリコール酸ナトリウムを含む、項目１４５に記載の剤形。
（項目１５７）
２５ｍｇのサイロシビン、ＳＭＣＣ ５０及びＳＭＣＣ ９０（ＳＭＣＣ ５０対ＳＭＣＣ ９０の比率が、１：６．４である）、ならびに約０．５％のデンプングリコール酸ナトリウムを含む、項目１４５に記載の剤形。
（項目１５８）
５ｍｇの結晶性サイロシビンＡ、１２．５ｍｇのＳＭＣＣ ５０、７９．５ｍｇのＳＭＣＣ ９０、１ｍｇのグリコール酸ナトリウムデンプン、１ｍｇのコロイド状二酸化ケイ素、及び１ｍｇのステアリルフマル酸ナトリウムを含む、項目１４５に記載の剤形。
（項目１５９）
前記結晶性サイロシビンが、少なくとも９５重量％の多形体Ａを含む、項目１４５～１５８のいずれか一項に記載の剤形。
（項目１６０）
前記剤形が、経口剤形である、項目１４５～１５８のいずれか一項に記載の剤形。
（項目１６１）
前記剤形が、カプセルである、項目１４５～１５８のいずれか一項に記載の剤形。
（項目１６２）
前記剤形が、錠剤である、項目１４５～１５８のいずれか一項に記載の剤形。
The foregoing is an illustrative description of the invention and should not be construed as a limitation thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.
In certain embodiments, for example, the following are provided:
(Item 1)
A method of treating depression in a subject in need thereof, said method comprising administering to said subject an effective amount of psilocybin or an active metabolite thereof.
(Item 2)
The subject has major depressive disorder, atypical depression, bipolar disorder, catatonic depression, depressive disorder due to a medical condition, postpartum depression, premenstrual dysphoric disorder, or seasonal The method of item 1, having an affective disorder.
(Item 3)
3. The method of item 2, wherein the subject has major depressive disorder.
(Item 4)
3. The method of item 2, wherein the subject has bipolar disorder.
(Item 5)
5. The method of item 4, wherein the subject has bipolar I disorder.
(Item 6)
5. The method of item 4, wherein the subject has bipolar disorder type II.
(Item 7)
7. The method of any one of items 1-6, wherein the depression is refractory to treatment.
(Item 8)
8. The method of any one of items 1-7, wherein at least one sign or symptom of depression is reduced.
(Item 9)
said signs or symptoms of depression are depressed mood, decreased interest in activities, weight loss or gain, decreased or increased appetite, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy; 9. The method of item 8, wherein feelings of worthlessness or excessive or inappropriate guilt, poor concentration or indecision, or suicidal ideation or behavior.
(Item 10)
10. The method of item 9, wherein the signs or symptoms of depression are measured according to diary assessment, clinician or caregiver assessment, clinical rating scales, or by functional MRI.
(Item 11)
The clinical depression rating scale includes the Brief Depressive Symptom Scale (QIDS)-16 Scale, QIDS-16 Daily Scale, Hamilton Depression Rating Scale, Beck Depression Inventory Scale, Montgomery-Asberg Depression Rating Scale, Clinical Global Impression Scale, 11. The method of item 10, which is the Zung Self-Rating Depression Scale, the Raskin Depression Rating Scale, and/or the Young Mania Rating Scale.
(Item 12)
The signs or symptoms of depression are assessed by Spielberger's Traits and Anxiety Inventory, Generalized Anxiety Disorder 7-Item Scale, Warwick-Edinburgh Mental Wellbeing Scale, Flourishing Scale, Snaith Hamilton's Anhedonia Pleasure Scale, Life Orientation Test, Meaning of Life Question Vote, Brief Resilience Scale, Nonfunctional Attitude Scale, 44-item Big Five Inventory, Peters 21-item Delusional Inventory, Test of Abnormal Self-Experiences, Contemplative Reaction Scale, Polar Bear Suppression Inventory, Barrett Impulsiveness Scale, Brief Experience Therapeutic Avoidance Questionnaire, Modified Tellegen Immersion Questionnaire, Scale for Assessing Therapeutic Relationships, Confidence/Expectation Questionnaire, Nature Connection Scale, Political Perspective Questionnaire, Social Connection Scale, Bech-Rafaelsen Mania the revised Santa Clara Concise Compassion Scale, the Appreciation Questionnaire, the Short Recommendation Scale, the Rosenberg Self-Esteem Scale, the Universality Subscale of the Mental Transcendence Scale, the Oxford Questionnaire on the Emotional Side Effects of Antidepressants, Lauks Affective Intensity Scale, Sexual Dysfunction Questionnaire, Brief Index of Female Sexual Function, Sexual Awareness Questionnaire, Barnes Akathisia Rating Scale, Occupational Productivity and Disability Questionnaire, Work and Social Adaptability Scale, Connectivity Questionnaire , Personality Standard Rating, Positive and Negative Syndrome Scale, Mastery Insight Scale, Self-Reflection and Insight Scale, Psychological Insight Scale, Metaphysical Belief Questionnaire, Spiritual Bypassing Scale, Adverse Early Childhood Experiences Questionnaire, Therapeutic Music Experiences Questionnaire, Setting Questionnaire, Musical Preoccupation Scale, Psychedelic Predictor Scale, Surrender Scale, EuroQOL-5 Dimensions-3 Level Scale, Columbia Suicide Severity Rating Scale, 11. The method of item 10, as measured using the Suicidal Idea Attribute Scale, or any combination thereof.
(Item 13)
11. The method of item 10, wherein said functional MRI measures the blood oxygen level dependent (BOLD) response of the amygdala.
(Item 14)
14. Method according to item 13, wherein the BOLD response is measured in a resting state, in response to an emotional face and/or music as a pleasurable stimulus.
(Item 15)
15. The method of any one of items 1-14, wherein at least one sign or symptom of depression is alleviated within 24 hours of administration of said psilocybin.
(Item 16)
15. The method of any one of items 1-14, wherein at least one symptom of depression is alleviated within one week of administration of said psilocybin.
(Item 17)
15. The method of any one of items 1-14, wherein at least one symptom of depression is alleviated for at least one month after administration of said psilocybin.
(Item 18)
15. The method of any one of items 1-14, wherein said at least one symptom of depression is alleviated for at least 3 months after administration of said psilocybin.
(Item 19)
15. The method of any one of items 1-14, wherein at least one symptom of depression is alleviated for at least 12 months after administration of said psilocybin.
(Item 20)
20. The method of any one of items 1-19, wherein no other treatment is administered to the subject to reduce the signs or symptoms of depression after administration of the psilocybin.
(Item 21)
20. The method of any one of items 1-19, further comprising administering to said subject at least one additional therapeutic agent for reducing said signs or symptoms of depression.
(Item 22)
the at least one additional therapeutic agent is a selective serotonin reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a tricyclic antidepressant, a tetracyclic antidepressant, a dopamine reuptake inhibitor, 5-HT 1A 22. The method of item 21, wherein the receptor antagonist, 5-HT2 receptor antagonist, 5-HT3 receptor antagonist, monoamine oxidase inhibitor, or noradrenergic antagonist.
(Item 23)
23. The method of item 21 or 22, wherein said at least one additional therapeutic agent is administered prior to administration of psilocybin.
(Item 24)
23. The method of item 21 or 22, wherein said at least one additional therapeutic agent is administered after administration of psilocybin.
(Item 25)
23. The method of item 21 or 22, wherein said at least one additional therapeutic agent is administered on the same day as said psilocybin.
(Item 26)
26. The method of any one of items 1-25, wherein the subject has not been previously exposed to psilocybin.
(Item 27)
26. The method of any one of items 1-25, wherein the subject has previously been exposed to psilocybin.
(Item 28)
28. The method of any one of items 1-27, wherein said subject has an additional comorbidity or disorder.
(Item 29)
29. The method of item 28, wherein the subject has an anxiety disorder, obsessive-compulsive disorder, alcoholism, personality disorder, cardiovascular disease, neurological disease, or cancer.
(Item 30)
30. The method of item 29, wherein the neurological disease is dementia, Alzheimer's disease, or Parkinson's disease.
(Item 31)
31. The method of any one of items 28-30, wherein reduction of at least one sign or symptom of depression in said subject treats or prevents one or more co-morbidities or disorders in said subject.
(Item 32)
32. The method of any one of items 1-31, wherein the subject is a mammal.
(Item 33)
33. The method of item 32, wherein the subject is a human.
(Item 34)
of items 1-33, wherein said psilocybin is administered in a dosage form comprising a therapeutically effective amount of highly pure crystalline psilocybin in the form of polymorph A, said crystalline psilocybin comprising at least 90% by weight of polymorph A. Any method described.
(Item 35)
35. The method of item 34, wherein said crystalline psilocybin comprises at least 95% by weight of polymorph A.
(Item 36)
36. The method of item 34 or 35, wherein said crystalline psilocybin has a chemical purity of greater than 97% by HPLC and no single impurity greater than 1%.
(Item 37)
Said psilocybin is administered in a dosage form comprising a therapeutically effective amount of highly pure crystalline psilocybin in the form of polymorph A, said crystalline psilocybin having a chemical purity of greater than 97% by HPLC and a purity of greater than 1%. 34. The method of any one of items 1-33, which does not have a single impurity.
(Item 38)
38. The method of item 37, wherein said highly pure crystalline psilocybin comprises at least 90% by weight of polymorph A.
(Item 39)
39. The method of item 38, wherein said highly pure crystalline psilocybin comprises at least 95% by weight of polymorph A.
(Item 40)
wherein said high purity crystalline psilocybin has either (i) a water content of less than 0.5 w/w% or (ii) a weight loss of less than 0.5 w/w% in the TGA thermogram from 25°C to 200°C. 40. A method according to any one of items 34-39, further characterized in that it comprises:
(Item 41)
of items 34-40, wherein said high purity crystalline psilocybin is further characterized by an endothermic event in a DSC thermogram having a first onset temperature of 145°C to 155°C and a second onset temperature of 205°C to 220°C A method according to any one of paragraphs.
(Item 42)
42. The method of any one of items 34-41, wherein said highly pure crystalline psilocybin is further characterized by one or more of: (a) loss on drying of 2 w/w % or less, (b) (c) 95-103 wt% assay (dry basis) as determined by HPLC; (d) 3000 ppm or less methanol, 5000 ppm ethanol as determined by HRGC. , THF of 720 ppm, and toluene of 890 ppm; (e) phosphoric acid content of 1 w/w% or less, as measured by 31 P NMR; and (f) (i) Cd of 1.5 ppm or less . (ii) Pb up to 1.5 ppm, (iii) As up to 4.5 ppm, (iv) Hg up to 9.0 ppm, (v) Co up to 15 ppm, (vi) V up to 30 ppm, (vii) Inductively Coupled Plasma Mass Spectrometry (ICP-MS) elemental analysis for Ni ≤60 ppm, (viii) Li ≤165 ppm, and (ix) Pd ≤30 ppm.
(Item 43)
43. The method of any one of items 34-42, wherein said highly pure crystalline psilocybin does not have a single impurity greater than 0.5%.
(Item 44)
44. The method of any of items 34-43, wherein said dosage form further comprises about 5-40 mg of said high purity crystalline psilocybin.
(Item 45)
45. The method of item 44, wherein the dosage form comprises 5 mg of highly purified crystalline psilocybin.
(Item 46)
45. The method of item 44, wherein the dosage form comprises about 10 mg of highly purified crystalline psilocybin.
(Item 47)
45. The method of item 44, wherein the dosage form comprises about 35 mg of highly purified crystalline psilocybin.
(Item 48)
48. The method of any one of items 34-47, wherein the dosage form comprises silicified microcrystalline cellulose.
(Item 49)
49. The method of item 48, wherein the silicified microcrystalline cellulose has a particle size range of about 45-150 microns.
(Item 50)
Further comprising a mixture of two silicified microcrystalline cellulose variants, said first variant having a particle size of about 45-80 microns and said second variant having a particle size of about 90-150 microns. , items 34-49.
(Item 51)
about 30% or less of the microcrystalline cellulose is the first variant having a particle size of about 45-80 microns, and about 70% or more of the microcrystalline cellulose has a particle size of about 90-150 microns. 51. The method of item 50, which is the second variant comprising:
(Item 52)
about 20% or less of the microcrystalline cellulose is the first variant having a particle size of about 45-80 microns, and about 80% or more of the microcrystalline cellulose has a particle size of about 90-150 microns. 51. The method of item 50, which is the second variant comprising:
(Item 53)
About 15% or less of said microcrystalline cellulose is said first variant having a particle size of about 45-80 microns, and about 85% or more of said microcrystalline cellulose has a particle size of about 90-150 microns. 51. The method of item 50, which is the second variant comprising:
(Item 54)
The dosage form comprises 5 mg crystalline psilocybin in the form of Polymorph A, 12.5 mg SMCC 50, 79.5 mg SMCC 90, 1 mg sodium starch glycolate, 1 mg colloidal silicon dioxide, and 1 mg stearyl 54. The method of item 53, comprising sodium fumarate.
(Item 55)
The dosage form comprises 1 mg crystalline psilocybin in the form of Polymorph A, 20.5 mg SMCC 50, 75.5 mg SMCC 90, 1 mg sodium starch glycolate, 1 mg colloidal silicon dioxide, and 1 mg stearyl 54. The method of item 53, comprising sodium fumarate.
(Item 56)
56. The method of any one of items 34-55, wherein said dosage form is an oral dosage form.
(Item 57)
57. The method of item 56, wherein the dosage form is a capsule.
(Item 58)
57. The method of item 56, wherein the dosage form is a tablet.
(Item 59)
59. The method of any one of items 1-58, wherein at least one dose of psilocybin is administered to said subject.
(Item 60)
60. The method of item 59, wherein said at least one dose of psilocybin is in the range of about 0.1 mg to about 100 mg.
(Item 61)
61. The method of item 60, wherein said dose of psilocybin is about 1 mg.
(Item 62)
61. The method of item 60, wherein said dose of psilocybin is about 10 mg.
(Item 63)
61. The method of item 60, wherein said dose of psilocybin is about 25 mg.
(Item 64)
59. The method of any one of items 1-58, wherein more than one dose of psilocybin is administered to said subject.
(Item 65)
66. The method of item 65, wherein at least two doses of psilocybin are administered to the subject.
(Item 66)
66. The method of any one of items 64-65, wherein said psilocybin is administered once daily.
(Item 67)
66. The method of any one of items 64-65, wherein said psilocybin is administered at least once a week.
(Item 68)
66. The method of any one of items 64-65, wherein said psilocybin is administered at least twice a week.
(Item 69)
66. The method of any one of items 64-65, wherein said psilocybin is administered at least once a month.
(Item 70)
66. The method of any one of items 64-65, wherein said psilocybin is administered at least twice a month.
(Item 71)
66. The method of any one of items 64-65, wherein said psilocybin is administered at least once every three months.
(Item 72)
66. The method of any one of items 64-65, wherein said psilocybin is administered at least once every six months.
(Item 73)
66. The method of any one of items 64-65, wherein said psilocybin is administered at least once every 12 months.
(Item 74)
74. The method of any one of items 64-73, wherein each dose of psilocybin administered is within the range of about 0.1 mg to about 100 mg.
(Item 75)
75. The method of item 74, wherein each dose of psilocybin administered is about 1 mg.
(Item 76)
75. The method of item 74, wherein each dose of psilocybin administered is about 10 mg.
(Item 77)
75. The method of item 74, wherein each dose of psilocybin administered is about 25 mg.
(Item 78)
wherein said psilocybin is administered via oral, intravenous, intramuscular, parenteral, topical, inhalation, rectal, transmucosal, intranasal, buccal, vaginal, intrathecal, intraocular, transdermal, intrauterine, intralymphatic routes; or by direct tissue or organ injection.
(Item 79)
79. The method of item 78, wherein said psilocybin is administered orally.
(Item 80)
80. The method of any one of items 1-79, wherein the subject participates in at least one psychological support session prior to administration of the psilocybin.
(Item 81)
81. The method of item 80, wherein the subject participates in at least three psychological support sessions prior to administration of the psilocybin.
(Item 82)
82. The method of any one of items 80-81, wherein at least one therapeutic intent is discussed during said psychological support session.
(Item 83)
83. The method of any one of items 80-82, wherein self-directed inquiry and empirical treatment are performed during said psychological support session.
(Item 84)
84. The method of any one of items 80-83, wherein the subject participates in at least one psychological support session after administration of the psilocybin.
(Item 85)
85. The method of item 84, wherein the subject participates in at least three psychological support sessions after administration of the psilocybin.
(Item 86)
86. The method of any one of items 80-85, wherein said psilocybin is administered to said subject in a room having a substantially non-clinical appearance.
(Item 87)
87. Method according to item 86, wherein the room comprises soft furniture.
(Item 88)
87. Method according to item 86, wherein the room is decorated using calm colors.
(Item 89)
87. Method according to item 86, wherein the room comprises a high definition sound system.
(Item 90)
89. Method according to any one of items 86-89, wherein said room comprises a bed or a sofa.
(Item 91)
91. The method of item 90, wherein the subject lies on a bed or sofa for about 4-8 hours, or a substantial percentage thereof, after administration of the psilocybin.
(Item 92)
92. The method of any one of items 86-91, wherein the subject listens to music for about 4-8 hours, or a substantial percentage thereof, after administration of the psilocybin.
(Item 93)
93. The method of any one of items 86-92, wherein the subject wears an eye mask for about 4-8 hours, or a substantial percentage thereof, after administration of the psilocybin.
(Item 94)
94. The method of any one of items 87-93, wherein a therapist provides psychological support to the subject for about 4-8 hours after administration of the psilocybin.
(Item 95)
95. Method according to item 94, wherein the therapist uses guided imagery and/or respiratory exercises to calm the subject and/or focus the subject's attention.
(Item 96)
95. The method of item 94, wherein the therapist provides reassuring physical contact with the subject.
(Item 97)
97. The method of item 96, wherein the therapist touches the subject's hand, arm, or shoulder.
(Item 98)
95. The method of item 94, wherein the therapist encourages the subject to perform a self-directed inquiry and empirical treatment.
(Item 99)
95. The method of item 94, wherein the therapist reminds the subject of at least one therapeutic intent.
(Item 100)
95. The method of item 94, wherein the therapist counsels the subject to do one or more of the following: (1) accepting feelings of anxiety; (2) allowing the experience to unfold naturally; (3) avoiding psychological resistance to the experience; (4) relaxing; and/or (5) exploring the subject's own mental space.
(Item 101)
95. The method of item 94, wherein said therapist does not initiate a conversation with said subject.
(Item 102)
95. The method of item 94, wherein the therapist responds to the subject if the subject initiates a conversation.
(Item 103)
103. The method of any one of items 80-102, wherein the psychological support is provided to the subject remotely.
(Item 104)
104. The method of item 103, wherein the psychological support is provided via a digital or electronic system.
(Item 105)
104. Method according to item 104, wherein said digital or said electronic system is a mobile phone app.
(Item 106)
106. The method of item 105, wherein the digital or electronic system is a website.
(Item 107)
A method according to the present claims.
(Item 108)
A formulation according to the present claims.
(Item 109)
Crystalline psilocybin according to the claims.
(Item 110)
A pharmaceutical dosage form comprising crystalline psilocybin as claimed in this claim.
(Item 111)
A method of treating a subject in need thereof comprising administering to said subject a therapeutically effective dose of psilocybin, said subject having at least one of the following diseases, disorders or conditions: , said methods: severe mood dysregulation disorder, major depressive disorder (MDD), treatment-resistant depression, persistent depressive disorder (dysthymia), premenstrual dysphoric disorder, substance/drug-induced depressive disorder, childbirth Post-depression or depressive disorder attributed to another medical condition, separation anxiety disorder, selective mutism, specific phobia, social anxiety disorder (social phobia), panic disorder, panic attacks, agoraphobia, generalized Anxiety disorders, substance-drug induced anxiety disorders, anxiety disorders attributed to other conditions, somatic symptom disorders, illness anxiety disorders (hypochondriasis), conversion disorders (functional neurosymptom disorders), factitious disorders, psychosocial Post-traumatic stress disorder (PTSD), adjustment disorder, acute distress disorder, obsessive-compulsive disorder, body dysmorphic disorder, hoarding disorder, trichotillomania (hair-pulling) disorder, scraping (skin picking) disorder, substance/drug-induced obsessive-compulsive and related disorders, obsessive-compulsive and related disorders due to another condition, substance-related disorders, alcohol-related disorders, cannabis-related disorders, hallucinogen-related disorders, inhalant-related disorders, ***e-related disorders, opioid-related disorders, sedative-related disorders , sedative-related or anxiolytic-related disorders, stimulant-related disorders, tobacco-related disorders, non-substance-related disorders (gambling or gaming disorders), migraines, cluster headaches such as chronic cluster headaches, periodic vomiting, nervousness type headache, incomplete aphasia, pica, anorexia nervosa, bulimia nervosa, bulimia nervosa, oppositional conduct disorder, intermittent explosive disorder, conduct disorder, antisocial personality disorder, psychopathy, pyromania, or Theft.
(Item 112)
A method of treating a subject in need thereof comprising administering to said subject a therapeutically effective dose of psilocybin, said subject having at least one of the following diseases, disorders or conditions: , said method: neurocognitive impairment due to Alzheimer's disease, Lewy bodies, traumatic brain injury, prion disease, HIV infection, Parkinson's disease, or Huntington's disease, concussion, chronic traumatic encephalopathy (CTE), speech impairment, speech Disorders (speech disorders), childhood-onset fluidity disorders (stuttering), social (practical) communication disorders, Tourette's disorders, persistent (chronic) movement or vocal tic disorders, amnestic disorders attributed to known physiological conditions , transient ischemic attack, cerebral infarction, cerebral hemorrhage, progressive polynuclear ophthalmoplegia, or retrograde amnesia.
(Item 113)
A method of treating a subject in need thereof comprising administering to said subject a therapeutically effective dose of psilocybin, said subject having at least one of the following diseases, disorders or conditions: , said method: Autism Spectrum Disorder or Antisocial Personality Disorder.
(Item 114)
A method of treating a subject in need thereof comprising administering to said subject a therapeutically effective dose of psilocybin, said subject having at least one of the following diseases, disorders or conditions: , said method: attention-deficit/hyperactivity disorder, other specified attention-deficit/hyperactivity disorder, or unspecified attention-deficit/hyperactivity disorder.
(Item 115)
A method of treating a subject in need thereof comprising administering to said subject a therapeutically effective dose of psilocybin, said subject having at least one of the following diseases, disorders or conditions: , said method: schizotypal (personality) disorder, delusional disorder, schizophrenia, or schizoaffective disorder.
(Item 116)
A method of treating a subject in need thereof comprising administering to said subject a therapeutically effective dose of psilocybin, said subject having at least one of the following diseases, disorders or conditions: , said method: female sexual interest/sexual arousal disorder, male hypoactive sexual desire disorder, or excessive sexual urge.
(Item 117)
A method of treating a subject in need thereof comprising administering to said subject a therapeutically effective dose of psilocybin, said subject having at least one of the following diseases, disorders or conditions: , said method: bipolar disorder type I, bipolar disorder type II, or cyclothymic disorder.
(Item 118)
A method of treating a subject in need thereof comprising administering to said subject a therapeutically effective dose of psilocybin, said subject having at least one of the following diseases, disorders or conditions: , said method: having at least one of: an insomnia disorder, a hypersomnia disorder, narcolepsy, or primary central sleep apnea.
(Item 119)
A method of treating a subject in need thereof comprising administering to said subject a therapeutically effective dose of psilocybin, said subject having at least one of the following diseases, disorders or conditions: , said method: schizophrenic personality disorder, schizotypal personality disorder, antisocial personality disorder, borderline personality disorder, or obsessive-compulsive personality disorder.
(Item 120)
A method of treating a subject in need thereof comprising administering to said subject a therapeutically effective dose of psilocybin, said subject having at least one of the following diseases, disorders or conditions: , said method: age-related hearing loss or tinnitus.
(Item 121)
A method of treating a subject in need thereof comprising administering to said subject a therapeutically effective dose of psilocybin, said subject having at least one of the following diseases, disorders or conditions: , said method: multiple sclerosis, cranial neuropathy, neuromyelitis optica, Bell's palsy, Guillain-Barre syndrome, demyelinating diseases of the central nervous system, or chronic inflammatory demyelinating polyneuropathy.
(Item 122)
A method of treating a subject in need thereof, said method comprising administering to said subject a therapeutically effective dose of psilocybin, said subject suffering from pain.
(Item 123)
A method of treating a subject in need thereof comprising administering to said subject a therapeutically effective dose of psilocybin, said subject having at least one of the following diseases, disorders or conditions: , said methods: myelopathy, traumatic brain injury, intellectual disability, mania, neurodegeneration, paraphilia disorder, suicidal behavior disorder, non-suicidal self-harm disorder, persistent complicated death disorder, gastrointestinal related disease, epilepsy , sickle cell disease, lock-in syndrome, restless legs syndrome, stroke, or amyotrophic lateral sclerosis (ALS).
(Item 124)
A method of treating a subject, said method comprising administering to said subject a therapeutically effective dose of psilocybin, wherein said subject exhibits improved cognition after administration.
(Item 125)
125. The method of item 124, wherein said improvement in cognition is improvement in attention, episodic memory, working memory, spatial memory, social cognition, executive function, and/or cognitive flexibility.
(Item 126)
A method of treating a subject in need thereof, said method comprising administering to said subject a therapeutically effective dose of psilocybin, said subject having treatment-resistant depression (TRD).
(Item 127)
A method of treating a subject in need thereof, said method comprising administering to said subject a therapeutically effective dose of psilocybin, said subject having Major Depressive Disorder (MDD).
(Item 128)
The method of any one of items 111-127, wherein said subject is a mammal.
(Item 129)
19. The method of item 18, wherein the subject is human.
(Item 130)
of items 111 to 129, wherein said psilocybin is administered in a dosage form comprising a therapeutically effective amount of highly pure crystalline psilocybin in the form of polymorph A, said crystalline psilocybin comprising at least 90% by weight of polymorph A. Any method described.
(Item 131)
131. The method of item 130, wherein said crystalline psilocybin comprises at least 95% by weight of polymorph A.
(Item 132)
132. The method of item 130 or 131, wherein said crystalline psilocybin has a chemical purity of greater than 97% by HPLC and no single impurity greater than 1%.
(Item 133)
Said psilocybin is administered in a dosage form comprising a therapeutically effective amount of highly pure crystalline psilocybin in the form of polymorph A, said crystalline psilocybin having a chemical purity of greater than 97% by HPLC and a purity of greater than 1%. 133. The method of any of items 111-132, which does not have a single impurity.
(Item 134)
Further comprising a mixture of two silicified microcrystalline cellulose variants, said first variant having a particle size of about 45-80 microns and said second variant having a particle size of about 90-150 microns. , items 130-133.
(Item 135)
about 30% or less of the microcrystalline cellulose is the first variant having a particle size of about 45-80 microns, and about 70% or more of the microcrystalline cellulose has a particle size of about 90-150 microns. 25. The method of item 24, which is a second variant comprising:
(Item 136)
136. The method of any one of items 130-135, wherein said dosage form is an oral dosage form.
(Item 137)
137. The method of item 136, wherein said dosage form is a capsule.
(Item 138)
137. The method of item 136, wherein said dosage form is a tablet.
(Item 139)
The method of any one of items 111-138, wherein at least one dose of psilocybin is administered to said subject.
(Item 140)
140. The method of item 139, wherein said at least one dose of psilocybin is in the range of about 0.1 mg to about 100 mg.
(Item 141)
141. The method of item 140, wherein said dose of psilocybin is about 25 mg.
(Item 142)
142. The method of any one of items 111-141, wherein the subject participates in at least one psychological support session prior to administration of the psilocybin.
(Item 143)
143. The method of item 142, wherein the subject participates in at least one psychological support session after administration of the psilocybin.
(Item 144)
144. The method of paragraphs 142 or 143, wherein a therapist provides psychological support to the subject for about 4-8 hours after administration of the psilocybin.
(Item 145)
1. A dosage form comprising a therapeutically effective amount of highly pure crystalline psilocybin in the form of polymorph A, said crystalline psilocybin comprising at least 90% by weight of polymorph A and comprising two silicified microcrystalline cellulose variants. further comprising a mixture, wherein the first variant has a particle size of about 45-80 microns (SMCC 50) and the second variant has a particle size of about 90-150 microns (SMCC 90) , the ratio of SMCC 50 to SMCC 90 is from 1:5 to 1:8 weight percent.
(Item 146)
146. The dosage form of item 145, further comprising a disintegrant, glidant, or lubricant.
(Item 147)
148. The dosage form of item 147, comprising a disintegrant, wherein the disintegrant is less than 3% (by weight), less than 2%, or less than 1% sodium starch glycolate.
(Item 148)
SMCC 50 to SMCC 90 ratio of 1:5 to 1:7, 1:6 to 1:7, 1:6 to 1:8, 1.7 to 1.8, 1:6, 1:6.1 , 1:6.2, 1:6.3, 1:6.4, 1:6.5, 1:6.6, 1.6.7, 1:6.8, 1.6.9, or Dosage form according to any one of items 145-147, which is 1:7.
(Item 149)
The dosage form of any one of items 145-147, comprising 5-40 mg of psilocybin.
(Item 150)
5 mg of psilocybin, SMCC 50 and SMCC 90 (the ratio of SMCC 50 to SMCC 90 is 1:6.4), and about 0.5% to 1.0% sodium starch glycolate, in item 145 Dosage form as described.
(Item 151)
146. The dosage form of item 145, comprising 5 mg of psilocybin, SMCC 50 and SMCC 90 (the ratio of SMCC 50 to SMCC 90 is 1:6.4), and about 0.5% sodium starch glycolate.
(Item 152)
146. The dosage form of item 145, comprising 10 mg of psilocybin, SMCC 50 and SMCC 90 (the ratio of SMCC 50 to SMCC 90 is 1:6.4), and about 1% sodium starch glycolate.
(Item 153)
Item 145, containing 10 mg of psilocybin, SMCC 50 and SMCC 90 (the ratio of SMCC 50 to SMCC 90 is 1:6.4), and about 0.5% to 1.0% sodium starch glycolate Dosage form as described.
(Item 154)
146. The dosage form of item 145, comprising 10 mg of psilocybin, SMCC 50 and SMCC 90 (the ratio of SMCC 50 to SMCC 90 is 1:6.4), and about 0.5% sodium starch glycolate.
(Item 155)
146. The dosage form of item 145, comprising 25 mg of psilocybin, SMCC 50 and SMCC 90 (the ratio of SMCC 50 to SMCC 90 is 1:6.4), and about 1% sodium starch glycolate.
(Item 156)
Item 145, containing 25 mg of psilocybin, SMCC 50 and SMCC 90 (the ratio of SMCC 50 to SMCC 90 is 1:6.4), and about 0.5% to 1.0% sodium starch glycolate Dosage form as described.
(Item 157)
146. The dosage form of item 145, comprising 25 mg of psilocybin, SMCC 50 and SMCC 90 (the ratio of SMCC 50 to SMCC 90 is 1:6.4), and about 0.5% sodium starch glycolate.
(Item 158)
146. The composition of claim 145, comprising 5 mg crystalline psilocybin A, 12.5 mg SMCC 50, 79.5 mg SMCC 90, 1 mg sodium starch glycolate, 1 mg colloidal silicon dioxide, and 1 mg sodium stearyl fumarate. dosage form.
(Item 159)
159. The dosage form of any one of items 145-158, wherein said crystalline psilocybin comprises at least 95% by weight of polymorph A.
(Item 160)
The dosage form of any one of items 145-158, wherein said dosage form is an oral dosage form.
(Item 161)
The dosage form of any one of items 145-158, wherein said dosage form is a capsule.
(Item 162)
Dosage form according to any one of items 145-158, wherein said dosage form is a tablet.
Claims (110)
Applications Claiming Priority (41)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962835484P | 2019-04-17 | 2019-04-17 | |
| US201962835472P | 2019-04-17 | 2019-04-17 | |
| US201962835477P | 2019-04-17 | 2019-04-17 | |
| US201962835449P | 2019-04-17 | 2019-04-17 | |
| US201962835474P | 2019-04-17 | 2019-04-17 | |
| US201962835476P | 2019-04-17 | 2019-04-17 | |
| US201962835481P | 2019-04-17 | 2019-04-17 | |
| US201962835460P | 2019-04-17 | 2019-04-17 | |
| US201962835480P | 2019-04-17 | 2019-04-17 | |
| US201962835479P | 2019-04-17 | 2019-04-17 | |
| US201962835478P | 2019-04-17 | 2019-04-17 | |
| US201962835465P | 2019-04-17 | 2019-04-17 | |
| US201962835464P | 2019-04-17 | 2019-04-17 | |
| US201962835450P | 2019-04-17 | 2019-04-17 | |
| US201962835485P | 2019-04-17 | 2019-04-17 | |
| US201962835458P | 2019-04-17 | 2019-04-17 | |
| US201962835482P | 2019-04-17 | 2019-04-17 | |
| US62/835,480 | 2019-04-17 | ||
| US62/835,478 | 2019-04-17 | ||
| US62/835,450 | 2019-04-17 | ||
| US62/835,449 | 2019-04-17 | ||
| US62/835,472 | 2019-04-17 | ||
| US62/835,484 | 2019-04-17 | ||
| US62/835,479 | 2019-04-17 | ||
| US62/835,476 | 2019-04-17 | ||
| US62/835,474 | 2019-04-17 | ||
| US62/835,460 | 2019-04-17 | ||
| US62/835,477 | 2019-04-17 | ||
| US62/835,482 | 2019-04-17 | ||
| US62/835,458 | 2019-04-17 | ||
| US62/835,465 | 2019-04-17 | ||
| US62/835,485 | 2019-04-17 | ||
| US62/835,481 | 2019-04-17 | ||
| US62/835,464 | 2019-04-17 | ||
| US201962893110P | 2019-08-28 | 2019-08-28 | |
| US62/893,110 | 2019-08-28 | ||
| US201962893611P | 2019-08-29 | 2019-08-29 | |
| US62/893,611 | 2019-08-29 | ||
| US201962946159P | 2019-12-10 | 2019-12-10 | |
| US62/946,159 | 2019-12-10 | ||
| PCT/IB2020/053688 WO2020212952A1 (en) | 2019-04-17 | 2020-04-17 | Treatment of depression and other various disorders with psilocybin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022529781A JP2022529781A (en) | 2022-06-24 |
| JPWO2020212952A5 true JPWO2020212952A5 (en) | 2023-04-25 |
Family
ID=70465167
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561958A Pending JP2022529781A (en) | 2019-04-17 | 2020-04-17 | Treatment of depression and various other disorders with psilocybin |
| JP2021561957A Pending JP2022529353A (en) | 2019-04-17 | 2020-04-17 | How to treat neurocognitive impairment, chronic pain and reduce inflammation |
| JP2021561959A Pending JP2022529476A (en) | 2019-04-17 | 2020-04-17 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561957A Pending JP2022529353A (en) | 2019-04-17 | 2020-04-17 | How to treat neurocognitive impairment, chronic pain and reduce inflammation |
| JP2021561959A Pending JP2022529476A (en) | 2019-04-17 | 2020-04-17 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US20230000883A1 (en) |
| EP (3) | EP3955918A1 (en) |
| JP (3) | JP2022529781A (en) |
| KR (3) | KR20220009955A (en) |
| CN (3) | CN114206349A (en) |
| AU (3) | AU2020258086A1 (en) |
| CA (3) | CA3138094A1 (en) |
| TW (1) | TW202103699A (en) |
| WO (3) | WO2020212952A1 (en) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11701348B1 (en) | 2016-07-23 | 2023-07-18 | Turtle Bear Holdings, Llc | Psilocybin compositions |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| AU2020231231A1 (en) * | 2019-03-07 | 2021-10-07 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| JP2022529781A (en) | 2019-04-17 | 2022-06-24 | コンパス パスファインダー リミテッド | Treatment of depression and various other disorders with psilocybin |
| WO2021067626A2 (en) | 2019-10-01 | 2021-04-08 | Intima Bioscience, Inc. | Genetic engineering of fungi to modulate tryptamine expression |
| WO2021072530A1 (en) * | 2019-10-15 | 2021-04-22 | Tassili Life Sciences, Corp. | Controlled release formulations of psilocybe-derived agents and method for their use, and methods and compositions for threating mild traumatic brain injury with post traumatic stress disorder. |
| WO2021108911A1 (en) * | 2019-12-04 | 2021-06-10 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| JP2023515616A (en) * | 2020-02-28 | 2023-04-13 | ユニヴェルシテートスピタル バーゼル | Suppressive effect after administration of 5HT2A agonist |
| CA3175211A1 (en) * | 2020-04-13 | 2021-10-21 | Matthias Emanuel LIECHTI | Lsd dose identification |
| EP4135713A4 (en) * | 2020-04-17 | 2024-04-17 | Revive Therapeutics Ltd | Use of psilocybin in the treatment of neurological brain injury and migraines |
| MX2022014605A (en) | 2020-05-19 | 2022-12-16 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use. |
| WO2021243460A1 (en) * | 2020-06-03 | 2021-12-09 | Neonmind Biosciences Inc. | Method for weight loss with therapy |
| WO2021243461A1 (en) * | 2020-06-04 | 2021-12-09 | Neonmind Biosciences Inc. | Use of lsd, esa, or dmt for weight loss. |
| WO2021250434A1 (en) | 2020-06-12 | 2021-12-16 | Beckley Psytech Limited | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
| MX2023004554A (en) | 2020-10-21 | 2023-05-08 | Compass Pathfinder Ltd | Use of benzodiazepines to increase sensitivity to psilocybin following a chronic ssri regimen. |
| WO2022115798A2 (en) * | 2020-11-30 | 2022-06-02 | Wesana Health Inc. | Compositions and methods for treating migraine |
| EP4251181A1 (en) * | 2020-11-30 | 2023-10-04 | Wesana Health Inc. | Compositions and methods for treating neurological conditions |
| WO2022123232A1 (en) * | 2020-12-07 | 2022-06-16 | Beckley Psytech Limited | Pharmaceutical composition comprising psilocybin or its polymorphs |
| WO2022125949A1 (en) * | 2020-12-13 | 2022-06-16 | Silo Pharma, Inc. | Use of psilocybin in cancer treatment |
| WO2022150563A1 (en) * | 2021-01-08 | 2022-07-14 | New York University | Treatment of suicidality with psilocin or psilocybin |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US20240131042A1 (en) * | 2021-02-16 | 2024-04-25 | Augusta University Research Institute, Inc. | Cannabidiol for treating neurodegenerative diseases |
| US20220273628A1 (en) * | 2021-02-19 | 2022-09-01 | Universitätsspital Basel | Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness |
| US20220265582A1 (en) * | 2021-02-24 | 2022-08-25 | Universitätsspital Basel | Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy |
| AU2022239961A1 (en) * | 2021-03-15 | 2023-09-28 | Tryp Therapeutics Inc. | Improved methods for the use of psychedelics |
| CN113017632B (en) * | 2021-03-17 | 2022-11-11 | 陈思 | Smart campus psychological consultation auxiliary method and system |
| CA3113414A1 (en) * | 2021-03-29 | 2022-09-29 | Mind Cure Health Inc. | Psychedelics protocol computer systems and methods |
| WO2022204802A1 (en) * | 2021-03-30 | 2022-10-06 | Mynd Life Sciences Inc. | Use of psychedelics to treat dementia |
| TW202304466A (en) | 2021-03-30 | 2023-02-01 | 英商康派斯開拓者公司 | Psilocybin compositions, methods of making and methods of using the same |
| US20220347195A1 (en) * | 2021-05-03 | 2022-11-03 | Mind Medicine, Inc. | Psychedelics for treatment of pain |
| WO2022235531A1 (en) * | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Movement disorders |
| US20220395499A1 (en) * | 2021-06-14 | 2022-12-15 | Mind Medicine, Inc. | Controlling effects after 5ht2a agonists administration |
| AU2022309017A1 (en) | 2021-07-07 | 2024-01-25 | Terran Biosciences Inc. | N,n-dimethyltryptamine and related psychedlics and uses thereof |
| WO2023281071A2 (en) * | 2021-07-09 | 2023-01-12 | Cybin Irl Limited | Integrated data collection devices for use in various therapeutic and wellness applications |
| WO2023012524A2 (en) * | 2021-08-03 | 2023-02-09 | Universitatsspital Basel | Lsd and psilocybin dose equivalence determination |
| AU2022342266A1 (en) * | 2021-09-08 | 2024-02-01 | Cybin Irl Limited | Combination drug therapies |
| WO2023077245A1 (en) * | 2021-11-08 | 2023-05-11 | Nova Mentis Life Science Corp. | Diagnosing, monitoring and treating neurological disease with psychoactive tryptamine derivatives and mrna measurements |
| AU2022387053A1 (en) * | 2021-11-09 | 2024-05-09 | Compass Pathfinder Limited | Treatment of treatment resistant depression with psilocybin |
| CA3237988A1 (en) | 2021-11-12 | 2023-05-19 | Terran Biosciences Inc. | Psilocybin and o-acetylpsilocin, salts and solid state forms thereof |
| WO2023086962A1 (en) * | 2021-11-12 | 2023-05-19 | Terran Biosciences Inc. | Psilocybin and o-acetylpsilocin, salts and solid state forms thereof |
| WO2023114097A1 (en) * | 2021-12-13 | 2023-06-22 | Compass Pathfinder Limited | Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression |
| WO2023135595A1 (en) * | 2022-01-11 | 2023-07-20 | Psyrx Ltd. | Combinations with psilocybin for treating gastrointestinal diseases or disorders |
| WO2023137325A1 (en) * | 2022-01-11 | 2023-07-20 | New York University | Treating alcohol use disorder using psilocybin |
| WO2023164092A1 (en) * | 2022-02-25 | 2023-08-31 | Parow Entheobiosciences Llc | Treatment of psychiatric disorders, brain injuries, and autism spectrum disorder |
| WO2023186832A1 (en) * | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine for the treatment of social/emotional withdrawal or detachment |
| WO2023186806A1 (en) * | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine for the treatment of bipolar disorder |
| WO2023186963A1 (en) * | 2022-03-31 | 2023-10-05 | Cybin Irl Limited | Combination of nitrous oxide and 5-ht2a receptor agonists |
| WO2023215338A1 (en) * | 2022-05-03 | 2023-11-09 | Wesana Health Inc. | Compositions and methods for treating cluster headache |
| WO2023212812A1 (en) * | 2022-05-03 | 2023-11-09 | Revive Therapeutics Ltd | Method and use of psilocybin in the prevention and treatment of stroke |
| WO2023215344A2 (en) * | 2022-05-03 | 2023-11-09 | Wesana Health Inc. | Compositions and methods for treating cluster-tic syndrome |
| WO2023215342A1 (en) * | 2022-05-03 | 2023-11-09 | Wesana Health Inc. | Compositions and methods for treating trigeminal neuralgia |
| WO2023215595A1 (en) * | 2022-05-05 | 2023-11-09 | Ananda Scientific, Inc. | Methods for the treatment of anxiety disorder |
| WO2023220363A1 (en) * | 2022-05-13 | 2023-11-16 | Reset Pharmaceuticals, Inc. | Administration of a psychedelic compound by intravenous infusion |
| WO2023238073A1 (en) * | 2022-06-08 | 2023-12-14 | Tryp Therapeutics Inc. | Treatment of binge eating disorder using psychedelics |
| WO2023247665A1 (en) | 2022-06-22 | 2023-12-28 | Cybin Irl Limited | Solid dispersions of psilocybin |
| US20240000795A1 (en) * | 2022-06-30 | 2024-01-04 | Terran Biosciences Inc. | Methods and compositions relating to controlling psychedelic effects with serotonin receptor modulators |
| WO2024019908A1 (en) * | 2022-07-19 | 2024-01-25 | Lobe Sciences Ltd. | Serotonergic psychedelic agent for treating selective mutism |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| GB202214721D0 (en) * | 2022-10-06 | 2022-11-23 | Rewire Therapeutics Ltd | A treatment for mental disorders |
| WO2024079648A1 (en) * | 2022-10-11 | 2024-04-18 | Sintalica S.R.L. | Delivery system for the controlled release of psychedelic compound, pharmaceutical composition and uses thereof |
Family Cites Families (493)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA672478A (en) | 1963-10-15 | Heim Roger | Psilocybin and psilocin | |
| GB911946A (en) | 1958-02-21 | 1962-12-05 | Sandoz Ltd | Psilocybin and psilocin and processes for their preparation |
| LU36879A1 (en) | 1958-02-21 | |||
| US3075992A (en) | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| BE582353A (en) | 1958-09-12 | |||
| US3192111A (en) | 1959-02-16 | 1965-06-29 | Sandoz Ltd | Method of inducing therapeutic tranquilization with psilocybin and psilocin |
| IE24138L (en) | 1959-02-18 | 1959-08-21 | Sandoz Ag | Psilocybin and psilocin |
| JPS5576859A (en) | 1978-12-01 | 1980-06-10 | Fujimoto Seiyaku Kk | Novel preparation of 4-hydroxyindole |
| JPS5728046A (en) | 1980-07-28 | 1982-02-15 | Nissan Chem Ind Ltd | Preparation of 4-substituted indole |
| US4499096A (en) | 1983-11-18 | 1985-02-12 | Lotsof Howard S | Rapid method for interrupting the narcotic addiction syndrome |
| EP0152379A3 (en) | 1984-02-15 | 1986-10-29 | Ciba-Geigy Ag | Process for preparing pharmaceutical compositions containing unilamellar liposomes |
| US4721612A (en) | 1984-04-12 | 1988-01-26 | The Liposome Company, Inc. | Steroidal liposomes |
| IL76591A0 (en) | 1984-10-05 | 1986-02-28 | Bioferon Biochem Substanz | Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof |
| US5785989A (en) | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
| US4587243A (en) | 1985-07-15 | 1986-05-06 | Lotsof Howard S | Rapid method for interrupting the ***e and amphetamine abuse syndrome |
| ATE107664T1 (en) | 1985-10-04 | 1994-07-15 | South African Inventions | REAGENTS AND METHODS. |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| EP0493380B1 (en) | 1989-09-05 | 1997-10-29 | University Of Utah Research Institute | Method and compositions for noninvasive dose-to-effect administration of lipophilic drugs |
| US5629307A (en) | 1989-10-20 | 1997-05-13 | Olney; John W. | Use of ibogaine in reducing excitotoxic brain damage |
| US5935925A (en) | 1990-05-08 | 1999-08-10 | Synaptic Pharmaceutical Corporation | Methods of treating migraine and compounds useful for such methods |
| US5626863A (en) | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| ATE233809T1 (en) | 1990-10-19 | 2003-03-15 | Univ New York | A METHOD OF TRANSPLANTING CELLS INTO THE BRAIN AND ITS THERAPEUTIC USE |
| US5827819A (en) | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| FR2675504B1 (en) | 1991-04-16 | 1995-01-27 | Delalande Sa | DERIVATIVES OF ARYL-3 OXAZOLIDINONE, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THERAPEUTICS. |
| US5468486A (en) | 1992-01-21 | 1995-11-21 | The University Of Tennessee Research Corporation | Vaccine containing a protein alkaloid conjugate for the treatment of fescue toxicosis |
| EP0566135A1 (en) | 1992-04-17 | 1993-10-20 | Takeda Chemical Industries, Ltd. | Transmucosal composition comprising a peptide and a cytidine derivative |
| US5871710A (en) | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
| US5573776A (en) | 1992-12-02 | 1996-11-12 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| HU220391B (en) | 1992-12-24 | 2002-01-28 | Farmitalia Carlo Erba S.R.L. | Ergoline derivatives of serotoninergic activity, pharmaceutical compositions containing the same process for their preparation |
| ES2068762B1 (en) | 1993-07-21 | 1995-12-01 | Lipotec Sa | A NEW PHARMACEUTICAL PREPARATION TO IMPROVE THE BIOAVAILABILITY OF DRUGS OF DIFFICULT ABSORPTION AND PROCEDURE FOR THEIR OBTAINING. |
| US5545617A (en) | 1993-11-12 | 1996-08-13 | The Schepens Eye Research Institute, Inc. | Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion |
| US20060019963A1 (en) | 1994-06-17 | 2006-01-26 | Smithkline Beecham Corporation | Compounds |
| ES2264562T3 (en) | 1994-07-25 | 2007-01-01 | Nda International, Inc. | USE OF NORIBOGAIN DERIVATIVES TO TREAT CHEMICAL DEPENDENCE IN MAMMALS. |
| US5874477A (en) | 1994-08-12 | 1999-02-23 | The University Of Hawaii | Method of treatment for malaria utilizing serotonin receptor ligands |
| US5696125A (en) | 1995-02-24 | 1997-12-09 | Research Foundation Of The State University Of New York | Substance abuse-induced hemorrhagic stoke in an animal model |
| US5643586A (en) | 1995-04-27 | 1997-07-01 | Perricone; Nicholas V. | Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds |
| US5942241A (en) | 1995-06-09 | 1999-08-24 | Euro-Celtique, S.A. | Formulations and methods for providing prolonged local anesthesia |
| US5879690A (en) | 1995-09-07 | 1999-03-09 | Perricone; Nicholas V. | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers |
| DE19542281C2 (en) | 1995-11-14 | 1997-12-04 | Boehringer Ingelheim Kg | Use of Epinastin for the treatment of migraines |
| FR2744361B1 (en) | 1996-02-07 | 1998-02-27 | Rhone Poulenc Rorer Sa | APPLICATION OF PYRROLIDINE DERIVATIVES TO THE PREPARATION OF DRUGS FOR THE TREATMENT OF DRUG ABUSE OR SUBSTANCES GIVEN TO PHARMACOMANIES OR EXCESSIVE USE |
| FR2744364B1 (en) | 1996-02-07 | 1998-02-27 | Rhone Poulenc Rorer Sa | APPLICATION OF UREIDOACETAMIDES TO THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DRUG ABUSE OR SUBSTANCES GIVEN TO PHARMACOMANIES OR EXCESSIVE USE |
| FR2744362B1 (en) | 1996-02-07 | 1998-02-27 | Rhone Poulenc Rorer Sa | APPLICATION OF PYRROLIDINE DERIVATIVES TO THE PREPARATION OF DRUGS FOR THE TREATMENT OF DRUG ABUSE OR SUBSTANCES GIVEN TO PHARMACOMANIES OR EXCESSIVE USE |
| FR2744363B1 (en) | 1996-02-07 | 1998-02-27 | Rhone Poulenc Rorer Sa | APPLICATION OF THIAZOLIDINE DERIVATIVES TO THE PREPARATION OF DRUGS FOR THE TREATMENT OF DRUG ABUSE OR SUBSTANCES GIVEN TO PHARMACOMANIA OR EXCESSIVE USE |
| AU2587297A (en) | 1996-03-25 | 1997-10-17 | Eli Lilly And Company | Method for treating pain |
| TW448171B (en) | 1996-06-06 | 2001-08-01 | Yamanouchi Pharma Co Ltd | Imidazole-substituted quinoxalinedione derivatives |
| AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5914129A (en) | 1996-07-23 | 1999-06-22 | Mauskop; Alexander | Analgesic composition for treatment of migraine headaches |
| US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
| US5958919A (en) | 1996-09-20 | 1999-09-28 | Washington University | Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration |
| US5891885A (en) | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
| US6479074B2 (en) | 1996-10-24 | 2002-11-12 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
| IL132784A (en) | 1997-05-07 | 2004-07-25 | Unimed Pharmaceutical Inc | Pharmaceutical compositions containing dronabinol |
| US5804592A (en) | 1997-05-30 | 1998-09-08 | Unimed Pharmaceuticals, Inc. | Method for improving disturbed behavior and elevating mood in humans |
| US6558956B1 (en) | 1997-06-24 | 2003-05-06 | The University Of Wyoming | Method and apparatus for detection of a controlled substance |
| GB9715082D0 (en) | 1997-07-17 | 1997-09-24 | Scherer Ltd R P | Treatment of attention deficit hyperactivity disorder and narcolepsy |
| US20010004644A1 (en) | 1997-07-21 | 2001-06-21 | Levin Bruce H. | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation |
| US7799337B2 (en) | 1997-07-21 | 2010-09-21 | Levin Bruce H | Method for directed intranasal administration of a composition |
| AU8915598A (en) | 1997-08-25 | 1999-03-16 | Pentech Pharmaceuticals, Inc. | Method for amelioration of social phobia |
| US7220737B1 (en) | 1997-09-04 | 2007-05-22 | Novoneuron, Inc | Noribogaine in the treatment of pain and drug addiction |
| CA2302754C (en) | 1997-09-04 | 2011-11-08 | Novoneuron, Inc. | Noribogaine in the treatment of pain and drug addiction |
| DE19738855C2 (en) | 1997-09-05 | 2001-01-04 | Lohmann Therapie Syst Lts | Transdermal therapeutic system with adhesive reservoir layer and unidirectional elastic back layer |
| US20030077227A1 (en) | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| US6228864B1 (en) | 1997-10-28 | 2001-05-08 | Vivus, Inc. | Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation |
| US5922341A (en) | 1997-10-28 | 1999-07-13 | Vivus, Incorporated | Local administration of pharmacologically active agents to treat premature ejaculation |
| US6037346A (en) | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| EP1027057A4 (en) | 1997-10-28 | 2003-01-02 | Vivus Inc | Treatment of female sexual dysfunction |
| ITTO980264A1 (en) | 1998-03-26 | 1999-09-26 | Silvio Rossi | APPLICATION OF A NON-QUATERNARY BASIC EXTRACT OF FUCHSIAEFOLIA PESCHIERA WITH ANTI-MALARICA ACTIVITY |
| EP1089736A2 (en) | 1998-06-22 | 2001-04-11 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
| AU4990599A (en) | 1998-07-14 | 2000-02-07 | Brigham And Women's Hospital | Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
| AU4984899A (en) | 1998-07-14 | 2000-02-07 | Adams Food Ltd. | Nutritionally active composition for hardening fingernails |
| JP2002520353A (en) | 1998-07-16 | 2002-07-09 | マサチューセッツ インスティテュート オブ テクノロジー | Compositions for the treatment of stress |
| MXPA01001180A (en) | 1998-07-31 | 2002-04-24 | Vela Pharmaceuticals Inc | Methods and compositions for treating and preventing substance abuse using moclobemide. |
| KR20010073153A (en) | 1998-09-18 | 2001-07-31 | 제임스 에이. 아노 | Serotonergic 5ht2 agonists for treating glaucoma |
| US20060025387A1 (en) | 1998-12-23 | 2006-02-02 | Cytoscan Sciences Llc | Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
| CA2360655C (en) | 1999-01-29 | 2007-03-20 | Losan Pharma Gmbh | Pharmaceutical compositions |
| ATE294577T1 (en) | 1999-02-24 | 2005-05-15 | Univ Cincinnati | USE OF SULFAMATE DERIVATIVES TO TREAT IMPULSIVE DISORDERS |
| EP1175246A4 (en) | 1999-03-19 | 2004-12-15 | Brigham & Womens Hospital | UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
| WO2000059481A1 (en) | 1999-04-06 | 2000-10-12 | Pharmaquest Ltd. | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| NZ514466A (en) | 1999-04-07 | 2004-10-29 | Pfizer Prod Inc | Use of CYP2D6 inhibitors in combination therapies |
| US6126924A (en) | 1999-05-27 | 2000-10-03 | Scales-Medeiros; Virginia A. | Light responsive self-tanning products and methods for use |
| US6495498B2 (en) | 1999-05-27 | 2002-12-17 | Johnson & Johnson Consumer Companies, Inc. | Detergent compositions with enhanced depositing, conditioning and softness capabilities |
| US6489341B1 (en) | 1999-06-02 | 2002-12-03 | Sepracor Inc. | Methods for the treatment of neuroleptic and related disorders using sertindole derivatives |
| US20080103179A1 (en) | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
| US6500459B1 (en) | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
| MXPA02001882A (en) | 1999-08-23 | 2002-08-20 | Univ Tulane | Modulation of the blood brain barrier transporter for leptin. |
| US6204245B1 (en) | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
| WO2001026642A2 (en) | 1999-10-08 | 2001-04-19 | Joyce Corinne Bechthold | Methods and compositions for treating neurobehavioral disorders |
| ES2162746B1 (en) | 1999-10-21 | 2003-02-16 | Lipotec Sa | MICROCAPSULES FOR THE STABILIZATION OF COSMETIC, PHARMACEUTICAL OR FOOD PRODUCTS. |
| US6693135B2 (en) | 2000-01-10 | 2004-02-17 | Nexmed (Holdings) Incorporated | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| CA2400803A1 (en) | 2000-01-18 | 2001-07-26 | Richard A. Stone | Ocular growth and nicotinic antagonists |
| US20030096831A1 (en) | 2000-01-18 | 2003-05-22 | Stone Richard A. | Ocular growth and nicotinic antagonists |
| FR2804603B1 (en) | 2000-02-04 | 2004-01-23 | Rhodia Chimie Sa | CONTINUOUS PROCESS FOR FORMULATING IN THE FORM OF GRANULES ONE OR MORE PHARMACEUTICAL ACTIVE SUBSTANCES |
| US20020015730A1 (en) | 2000-03-09 | 2002-02-07 | Torsten Hoffmann | Pharmaceutical formulations and method for making |
| AU2001243369A1 (en) | 2000-03-14 | 2001-09-24 | Massachusetts Institute Of Technology | Composition and method to treat weight gain and obesity attributable to psychotropic drugs |
| DE10014588A1 (en) | 2000-03-27 | 2001-10-04 | Basf Ag | Sustained-release oral dosage form that floats in gastric fluid includes a blend of polyvinyl acetate and polyvinylpyrrolidone |
| WO2001072839A2 (en) | 2000-03-27 | 2001-10-04 | Pe Corporation (Ny) | Human g-protein coupled receptors |
| US6380176B2 (en) | 2000-03-28 | 2002-04-30 | Ajinomoto Co., Inc. | Method for inhibiting non-intentional behavior with a running neuron inhibitory substance |
| DE10018834A1 (en) | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermal or transmucosal pharmaceutical dosage form for treatment of nicotine dependence or smoking withdrawal contains nicotine compound or substitute and CNS active compound |
| AU6106801A (en) | 2000-04-28 | 2001-11-12 | Gary W. Neal | Trans-clitoral administration of therapy |
| ES2303527T3 (en) | 2000-05-10 | 2008-08-16 | Jagotec Ag | GRINDING PROCEDURE. |
| US20070059367A1 (en) | 2000-06-06 | 2007-03-15 | Cherukuri S R | Drug Delivery System and Associated Methods |
| US20020044962A1 (en) | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
| US20020019421A1 (en) | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
| AU2001281416A1 (en) | 2000-07-19 | 2002-01-30 | Pitmy International N.V. | Transportation of nucleic acid substances |
| AU2001291114A1 (en) | 2000-09-19 | 2002-04-02 | Microbia, Inc. | Modulation of secondary metabolite production by zinc binuclear cluster proteins |
| US9399050B2 (en) | 2000-10-04 | 2016-07-26 | Paul Edward Stamets | Controlling insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi |
| US9474776B2 (en) | 2000-10-04 | 2016-10-25 | Paul Edward Stamets | Integrative fungal solutions for protecting bees |
| US20030119884A1 (en) | 2000-11-01 | 2003-06-26 | Epstein Mel H. | Methods and compositions for regulating memory consolidation |
| US20070100000A1 (en) | 2000-11-01 | 2007-05-03 | Epstein Mel H | Methods of providing neuroprotection |
| AR031473A1 (en) | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | GABA INTENSIFIERS IN THE TREATMENT OF DISEASES RELATED TO A REDUCED NEUROSTEROID ACTIVITY |
| CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| US6495154B1 (en) | 2000-11-21 | 2002-12-17 | Vivus Inc. | On demand administration of clomipramine and salts thereof to treat premature ejaculation |
| IL139975A0 (en) | 2000-11-29 | 2002-02-10 | Univ Ramot | Anti proliferative drugs |
| CA2430298A1 (en) | 2000-11-30 | 2002-06-06 | Banavara Lakshman Mylari | Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
| SK6092003A3 (en) | 2000-11-30 | 2004-07-07 | Pfizer Prod Inc | Combination of GABA agonists and aldosereductase inhibitors |
| US20050176790A1 (en) | 2001-02-28 | 2005-08-11 | Johannes Bartholomaus | Pharmaceutical salts |
| US20020137785A1 (en) | 2001-03-26 | 2002-09-26 | George Kindness | Inflammatory mechanism modulator composition and methods with anti-asthmatic properties |
| US20050096396A1 (en) | 2002-03-28 | 2005-05-05 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| WO2002078643A2 (en) | 2001-03-30 | 2002-10-10 | Philadelphia Health And Education Corporation | Immunomodulation and effect on cell processes relating to serotonin family receptors |
| US6632217B2 (en) | 2001-04-19 | 2003-10-14 | Microsolutions, Inc. | Implantable osmotic pump |
| EP1423114A4 (en) | 2001-05-04 | 2006-05-17 | Merck & Co Inc | Method and compositions for treating migraines |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US20040023952A1 (en) | 2001-06-20 | 2004-02-05 | Leventhal Audie G. | Enhanced brain function by gaba-ergic stimulation |
| WO2003016903A2 (en) | 2001-08-20 | 2003-02-27 | Walter Pils | Device and method for determining an analyte |
| US6541043B2 (en) | 2001-08-28 | 2003-04-01 | Dexgen Pharmaceuticals, Inc. | Method and synergistic composition for treating attention deficit/hyperactivity disorder |
| EP1429728A1 (en) | 2001-08-29 | 2004-06-23 | SRL Technologies, Inc. | Sustained release preparations |
| JP4516748B2 (en) | 2001-09-14 | 2010-08-04 | サイトス バイオテクノロジー アーゲー | Packaging immunostimulatory substances in virus-like particles: preparation and use |
| JP4360906B2 (en) | 2001-09-14 | 2009-11-11 | サイトス バイオテクノロジー アーゲー | In vivo activation of antigen-presenting cells to enhance the immune response induced by virus-like particles |
| MXPA04002496A (en) | 2001-09-27 | 2004-05-31 | Pharmacia Ab | Pharmaceutical compositions for the treatment of urinary disorders. |
| US7544681B2 (en) | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| US6592901B2 (en) | 2001-10-15 | 2003-07-15 | Hercules Incorporated | Highly compressible ethylcellulose for tableting |
| US20060264508A1 (en) | 2001-10-16 | 2006-11-23 | Stone Richard A | Modulation of ocular growth and myopia by gaba drugs |
| US20030082225A1 (en) | 2001-10-19 | 2003-05-01 | Mason Paul Arthur | Sterile, breathable patch for treating wound pain |
| US7045543B2 (en) | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
| EP1453468A4 (en) | 2001-11-09 | 2005-11-23 | Chiron Corp | Method of vaccinating a human patient to prevent metastatic tumors |
| GB0127832D0 (en) | 2001-11-20 | 2002-01-09 | Jagotec Ag | Method for the preparation of pharmaceutical nanosuspensions |
| EP1451156A4 (en) | 2001-11-27 | 2005-05-25 | Merck & Co Inc | 4-aminoquinoline compounds |
| AU2002352878B2 (en) | 2001-11-27 | 2007-11-22 | Merck Sharp & Dohme Corp. | 2-Aminoquinoline compounds |
| WO2003047551A1 (en) | 2001-11-29 | 2003-06-12 | Penwest Pharmaceutical Company | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
| US7241797B2 (en) | 2002-01-23 | 2007-07-10 | University Of Cincinnati | Method of increasing milk production |
| US20030171435A1 (en) | 2002-01-23 | 2003-09-11 | Drug Abuse Sciences, Inc. | New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them |
| DE60308647T2 (en) | 2002-02-07 | 2007-08-09 | Pharmacia Corp. | PHARMACEUTICAL FORM FOR MUCOSAL ADMINISTRATION |
| ES2274248T3 (en) | 2002-02-07 | 2007-05-16 | Pharmacia Corporation | COMPRESSED PHARMACEUTICAL. |
| US20030153552A1 (en) | 2002-02-14 | 2003-08-14 | Mash Deborah C. | Method of treating chemical dependency in mammals and a composition therefor |
| US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| DE10208335A1 (en) | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Pharmaceutical form and process for its preparation |
| US20030199439A1 (en) | 2002-04-22 | 2003-10-23 | Simon David Lew | Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics |
| AU2003225206B2 (en) | 2002-04-24 | 2008-02-14 | Forest Laboratories Holdings Limited | Prevention and treatment of functional somatic disorders, including stress-related disorders |
| WO2003092676A1 (en) | 2002-04-29 | 2003-11-13 | The General Hospital Corporation | Compositions and methods for preventing abuse of orally administered medications |
| AUPS317102A0 (en) | 2002-06-25 | 2002-07-18 | Drug Delivery Solutions Pty Ltd | Transdermal aerosol compositions |
| WO2004003145A2 (en) | 2002-06-28 | 2004-01-08 | Nastech Pharmaceutical Company Inc. | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| US20040006043A1 (en) | 2002-07-02 | 2004-01-08 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Methods, pharmaceutical compositions and pharmaceutical kits for enhancing the therapeutic efficiency of cancer chemotherapeutic agents |
| US10738268B2 (en) | 2016-08-21 | 2020-08-11 | Insectergy, Llc | Cannabis nanoemulsion methods |
| US20050148673A1 (en) | 2002-07-11 | 2005-07-07 | Harbut Ronald E. | Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition |
| EP1532167B1 (en) | 2002-07-17 | 2012-01-25 | Cytos Biotechnology AG | Molecular antigen arrays using a virus like particle derived from the ap205 coat protein |
| NZ537003A (en) | 2002-07-18 | 2008-03-28 | Cytos Biotechnology Ag | Hapten-carrier conjugates comprising virus like particles and uses thereof |
| US7838034B2 (en) | 2002-07-30 | 2010-11-23 | Grunenthal Gmbh | Intravenous pharmaceutical form of administration |
| JPWO2004014429A1 (en) | 2002-08-09 | 2005-12-02 | 三菱ウェルファーマ株式会社 | Psychiatric disorder vulnerability control agent |
| US20030114512A1 (en) | 2002-09-09 | 2003-06-19 | Collier Robert J | Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma |
| WO2004025268A2 (en) | 2002-09-13 | 2004-03-25 | Carnegie Mellon University | Optical biosensors and methods of use thereof |
| US20060183744A1 (en) | 2002-09-19 | 2006-08-17 | Rohrer Susan P | Method for treating depression and/or anxiety |
| US6913768B2 (en) | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
| DE10244504A1 (en) | 2002-09-25 | 2004-04-08 | Capsulution Nanoscience Ag | Quick-release dosage form with poorly soluble active ingredient |
| EP1551370B1 (en) | 2002-10-11 | 2007-12-19 | Idea Ag | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| US7132122B2 (en) | 2002-10-30 | 2006-11-07 | The Regents Of The University Of California | Direct micro-patterning of lipid bilayers using UV light and selected uses thereof |
| DE10250944B9 (en) | 2002-10-31 | 2004-09-16 | Cell Center Cologne Gmbh | Use a pen to apply care or active ingredients to the nose |
| US7670627B2 (en) | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
| BR0317747A (en) | 2002-12-24 | 2005-11-22 | Neurochem Int Ltd | Method of concomitant therapeutic treatment of an individual, pharmaceutical composition, kit, use of a first agent and a second agent, and methods of preventing or treating amyloid-b-related disease, alzheimer's disease and mild cognitive impairment |
| KR101095939B1 (en) | 2003-01-16 | 2011-12-19 | 아카디아 파마슈티칼스 인코포레이티드 | Selective serotonin 2??2? receptor inverse agonists as therapeutices for neurodegenerative diseases |
| BRPI0406592A (en) | 2003-01-23 | 2005-12-20 | Acadia Pharm Inc | Uses of n-desmethylclozapine, methods for treating psychosis, affective disorders, dementia, neuropathic pain and glaucoma and pharmaceutical composition |
| US20040186155A1 (en) | 2003-01-30 | 2004-09-23 | Dayno Jeffrey Marc | Combination therapy for the treatment or prevention of migraine |
| EP1603548A4 (en) | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | Method and composition for treating neurodegenerative disorders |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| ES2487415T3 (en) | 2003-03-17 | 2014-08-20 | Neurohealing Pharmaceuticals, Inc. | High potency dopaminergic treatment of neurological deficiencies associated with brain lesions |
| CA2517675A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
| US8906413B2 (en) | 2003-05-12 | 2014-12-09 | Supernus Pharmaceuticals, Inc. | Drug formulations having reduced abuse potential |
| SI1644019T2 (en) | 2003-05-29 | 2018-04-30 | Shire Llc | Abuse resistant amphetamine compounds |
| WO2004108130A1 (en) | 2003-06-03 | 2004-12-16 | Beth Israel Deaconess Medical Center | Methods and compounds for the treatment of vascular stenosis |
| EP1644004A4 (en) | 2003-06-20 | 2010-10-06 | Ronald Aung-Din | Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
| WO2005007628A1 (en) | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| JP4174016B2 (en) | 2003-07-11 | 2008-10-29 | 株式会社ビーエル | Immunochromatographic detection method and test kit for thylosins by competitive method |
| DE10334188B4 (en) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Use of rotigotine to treat depression |
| DE10338174A1 (en) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermal drug formulations with drug combinations for the treatment of Parkinson's disease |
| US20050203011A1 (en) | 2003-09-19 | 2005-09-15 | The Regents Of The University Of California | Mitigating symptoms and behaviors of substance abuse by modulating GDNF or BDNF pathway activity |
| US20050070501A1 (en) | 2003-09-29 | 2005-03-31 | New York Blood Center, Inc. | Water dispersible film |
| PT1670444E (en) | 2003-10-03 | 2011-07-29 | Veijlen N V | Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases |
| US7517900B2 (en) | 2003-10-10 | 2009-04-14 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| WO2005039502A2 (en) | 2003-10-24 | 2005-05-06 | Azopax Therapeutics Llc | Macromer-melt formulations |
| US20070053954A1 (en) | 2003-10-24 | 2007-03-08 | Rowe Stephen C | Macromer-melt formulations |
| JP2005132747A (en) | 2003-10-29 | 2005-05-26 | Ajinomoto Co Inc | Aged pet ageing behavior-improving agent |
| CN1917876A (en) | 2003-12-16 | 2007-02-21 | Cns生物有限公司 | Methods and compositions |
| US20050260258A1 (en) | 2003-12-18 | 2005-11-24 | The Texas A&M University System | Use of vitelline protein B as a microencapsulating additive |
| WO2005063248A1 (en) | 2003-12-22 | 2005-07-14 | Sepracor Inc. | Modafinil combination therapy for improving sleep quality |
| WO2005063296A2 (en) | 2003-12-23 | 2005-07-14 | Pfizer Products Inc. | Therapeutic combination for cognition enhancement and psychotic disorders |
| GB0400802D0 (en) | 2004-01-14 | 2004-02-18 | Daniolabs Ltd | Compounds for the treatment of disease |
| WO2005072705A1 (en) | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
| US20050209218A1 (en) | 2004-02-13 | 2005-09-22 | Meyerson Laurence R | Methods and compositions for the treatment of psychiatric conditions |
| WO2005079773A2 (en) | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders |
| US7981441B2 (en) | 2004-02-18 | 2011-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | Drug delivery systems using mesoporous oxide films |
| US20050222270A1 (en) | 2004-02-26 | 2005-10-06 | Olney John W | Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis |
| FR2867075B1 (en) | 2004-03-03 | 2006-07-14 | Ethypharm Sa | PROCESS FOR PREPARING CALIBRATED BIODEGRADABLE MICROSPHERES |
| US7629475B2 (en) | 2004-03-12 | 2009-12-08 | The Mclean Hospital Corporation | Salvinorin derivatives and uses thereof |
| US20060270592A1 (en) | 2004-03-19 | 2006-11-30 | Ophthalmic Research Associates, Inc. | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
| CA2567249A1 (en) | 2004-04-19 | 2006-10-05 | Jds Pharmaceuticals, Llc | Lithium combinations, and uses related thereto |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| RU2253461C1 (en) | 2004-04-30 | 2005-06-10 | Общество с ограниченной ответственностью "Паркинфарм" | Pharmaceutical combination influencing central nervous system function; method of correcting conditions associated with dysfunction of central nervous system; pharmaceutical kit; agent assisting therapeutical substances and metabolites to cross blood-brain barrier; and endonasal drug |
| US20050255091A1 (en) | 2004-05-14 | 2005-11-17 | Loomis Gary L | Hydrogels for biomedical applications |
| US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US20050265955A1 (en) | 2004-05-28 | 2005-12-01 | Mallinckrodt Inc. | Sustained release preparations |
| NL1026634C2 (en) | 2004-07-12 | 2006-01-16 | Willem Jacob Van Der Burg | Psychopharmaceutical preparation and active ingredient. |
| US7799802B2 (en) | 2004-08-03 | 2010-09-21 | Institstute of Oriental Medical Science Inc. | Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation |
| US20060030625A1 (en) | 2004-08-06 | 2006-02-09 | Cheryle Ram Hart | Dietary neurotransmitter precursors for balanced synthesis of neurotransmitters |
| US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| SG155257A1 (en) | 2004-09-24 | 2009-09-30 | Beth Israel Hospital | Methods of diagnosing and treating complications of pregnancy |
| EP1799640A4 (en) | 2004-09-27 | 2009-09-02 | Organix Inc | Indole compounds useful as serotonin selective agents |
| EP1799264A2 (en) | 2004-10-08 | 2007-06-27 | Neuromolecular Pharmaceuticals Inc | Methods and compositions for treating migraine pain |
| US20090169566A1 (en) | 2004-11-22 | 2009-07-02 | Anadis Ltd. | Bioactive compositions |
| FR2878161B1 (en) | 2004-11-23 | 2008-10-31 | Flamel Technologies Sa | ORAL MEDICINE FORM, SOLID AND DESIGNED TO AVOID MEASUREMENT |
| US20060110327A1 (en) | 2004-11-24 | 2006-05-25 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
| FR2878158B1 (en) | 2004-11-24 | 2009-01-16 | Flamel Technologies Sa | ORAL PHARMACEUTICAL FORM, SOLID MICROPARTICULAR DESIGNED TO PREVENT MEASUREMENT |
| US7294649B2 (en) | 2004-12-17 | 2007-11-13 | Roche Diagnostics Operatins, Inc. | Methamphetamine derivatives and conjugates for immunoassay |
| US8512751B2 (en) | 2004-12-20 | 2013-08-20 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
| EP1844189B1 (en) | 2005-01-10 | 2020-10-28 | Smiths Detection Inc. | Method for preparing a sampling swab |
| DE102005004343A1 (en) | 2005-01-25 | 2006-08-10 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Treatment of phantom phenomena |
| FR2881652B1 (en) | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING |
| US8318210B2 (en) | 2005-02-28 | 2012-11-27 | Neos Therapeutics, Lp | Compositions and methods of making sustained release liquid formulations |
| PL1885342T3 (en) | 2005-03-21 | 2016-10-31 | Crystallization inhibitor and its use in gelatin capsules | |
| JP2008534562A (en) | 2005-03-28 | 2008-08-28 | オレクソ・アクチエボラゲット | New pharmaceutical compositions useful for the treatment of migraine |
| US20060229293A1 (en) | 2005-04-06 | 2006-10-12 | Addiction Research Institute, Inc. | Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C |
| BRPI0612440A2 (en) | 2005-04-08 | 2010-11-23 | New River Pharmaceuticals Inc | pharmaceutical composition and use of an amphetamine prodrug |
| WO2007004067A2 (en) | 2005-04-15 | 2007-01-11 | Interface Biologics Inc. | Methods and compositions for the delivery of biologically active agents |
| WO2006113557A2 (en) | 2005-04-15 | 2006-10-26 | Board Of Trustees Of Michigan State University | Gpcr modulators |
| JP2008538575A (en) | 2005-04-22 | 2008-10-30 | ワイス | Benzodioxane and benzodioxolane derivatives and their use |
| JP4899012B2 (en) | 2005-05-06 | 2012-03-21 | スミス・ディテクション・インコーポレイテッド | Improved chemical detection of peroxide-based explosives |
| US8859585B2 (en) | 2005-05-25 | 2014-10-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Scopolamine for the treatment of depression and anxiety |
| GB0511060D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| WO2006131923A2 (en) | 2005-06-07 | 2006-12-14 | Ramot At Tel Aviv University Ltd. | Novel salts of conjugated psychotropic drugs and processes of preparing same |
| AU2006259224B2 (en) | 2005-06-16 | 2012-08-23 | Mohammed Saeed | Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent |
| US7645802B2 (en) | 2005-06-27 | 2010-01-12 | Biovail Laboratories International Srl. | Bupropion hydrobromide and therapeutic applications |
| EP1906937B1 (en) | 2005-07-22 | 2016-10-19 | Rubicon Research Pvt Ltd. | Novel dispersible tablet composition |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| US20070092586A1 (en) | 2005-10-26 | 2007-04-26 | Alamo Pharmaceuticals | Compositions and methods for the administration psychotropic drugs which modulate body weight |
| DE102005055866A1 (en) | 2005-11-23 | 2007-05-24 | Hte Ag The High Throughput Experimentation Company | Continuous reaction of two liquid, mutually immiscible phases especially in Suzuki (hetero)aryl-(hetero)aryl coupling reactions involves flowing components through packed bed reactor |
| EP1991207A2 (en) | 2006-01-21 | 2008-11-19 | Abbott GmbH & Co. KG | Dosage form and method for the delivery of drugs of abuse |
| CN101336116B (en) | 2006-02-02 | 2013-01-02 | 医学技术设备公司 | Bioactive material delivery systems comprising sol-gel compositions |
| US20070203216A1 (en) | 2006-02-14 | 2007-08-30 | Bjarke Ebert | Method of treating inflammatory diseases |
| US20070190130A1 (en) | 2006-02-16 | 2007-08-16 | Mark William A | Protein hydrolysate excipients |
| US20080075789A1 (en) | 2006-02-28 | 2008-03-27 | The Regents Of The University Of California | Genes differentially expressed in bipolar disorder and/or schizophrenia |
| CA2644311C (en) | 2006-03-01 | 2012-07-10 | Tristrata, Inc. | Composition and method for topical treatment of tar-responsive dermatological disorders |
| FR2898271B1 (en) | 2006-03-09 | 2009-01-16 | Pierre Fabre Medicament Sa | NOVEL USE OF ANTIHISTAMINE AGENTS FOR PREVENTIVE TREATMENT OR METHOD OF INFLAMMATORY SYNDROMES, IN PARTICULAR THOSE TRIGGED BY TOGA VIRUSES. |
| US8785500B2 (en) | 2006-03-22 | 2014-07-22 | Icahn School Of Medicine At Mount Sinai | Intranasal administration of ketamine to treat depression |
| WO2006079999A2 (en) | 2006-04-09 | 2006-08-03 | Barth Frederik H | Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist |
| EP2010584A4 (en) | 2006-04-14 | 2010-07-21 | Interface Biologics Inc | Grafted polymers and uses thereof |
| GB0608647D0 (en) | 2006-05-02 | 2006-06-14 | Haritou Susan J A | Methods of diagnosis and treatment |
| MX2008014455A (en) | 2006-05-12 | 2008-11-27 | Shire Llc | Controlled dose drug delivery system. |
| US8846100B2 (en) | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
| EP1948155B1 (en) | 2006-06-28 | 2012-03-07 | Chelsea Therapeutics Inc. | Pharmaceutical compositions comprising droxidopa |
| WO2008053362A2 (en) | 2006-06-30 | 2008-05-08 | Interface Biologics, Inc. | Bioresponsive polymers |
| KR20090048462A (en) | 2006-07-17 | 2009-05-13 | 라모트 앳 텔-아비브 유니버시티 리미티드 | Gaba conjugates for pain |
| AU2007276631A1 (en) | 2006-07-20 | 2008-01-24 | Cascade Therapeutics Inc. | Tetrahydro-5H-pyrido[2,3-d]azepines as 5-HT2c ligands |
| US20080026189A1 (en) | 2006-07-27 | 2008-01-31 | Chun-Wei Lin | Thin key structure for generating dazzling light |
| CA2661495C (en) | 2006-08-23 | 2017-05-02 | The University Of Montana | Method of reducing neuronal cell damage |
| SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
| WO2008026046A1 (en) | 2006-08-30 | 2008-03-06 | Pfizer Products Inc. | Morpholine d3 dopamine antagonists |
| CA2660732A1 (en) | 2006-08-31 | 2008-03-06 | Biogen Idec Ma Inc. | Methods relating to peripheral administration of nogo receptor polypeptides |
| EP2066355A2 (en) | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
| US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| WO2008039179A1 (en) | 2006-09-26 | 2008-04-03 | Addiction Research Institute, Inc. | Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c |
| WO2008038291A1 (en) | 2006-09-27 | 2008-04-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy |
| CA2667510A1 (en) | 2006-10-27 | 2008-06-12 | Janssen Pharmaceutica N.V. | Methods for treating disruptive behavior disorders |
| BRPI0718437A2 (en) | 2006-10-27 | 2013-11-19 | Medivation Neurology Inc | COMBINATION METHODS AND THERAPIES TO TREAT ALZHEIMER'S DISEASE USING DIMEBON AND DOLEPEZIL |
| CN101568333A (en) | 2006-10-31 | 2009-10-28 | 詹森药业有限公司 | Treatment of pervasive developmental disorders |
| US20080293695A1 (en) | 2007-05-22 | 2008-11-27 | David William Bristol | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance |
| US8653106B2 (en) | 2010-07-30 | 2014-02-18 | Pisgah Laboratories, Inc. | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder |
| US7718649B1 (en) | 2006-11-10 | 2010-05-18 | Pisgah Labs, Inc. | Physical states of a pharmaceutical drug substance |
| JP2010512413A (en) | 2006-12-11 | 2010-04-22 | ケムファーム・インコーポレーテッド | Non-standard amino acid conjugates of amphetamine and methods for their production and use |
| ES2302650B1 (en) | 2007-01-11 | 2009-02-16 | Tedec-Meiji Farma, S.A. | COMPOSITION OF FAST DISINTEGRATION IN THE ORAL CAVITY. |
| WO2008095086A2 (en) | 2007-01-31 | 2008-08-07 | University Of Virginia Patent Foundation | Topiramate plus naltrexone for the treatment of addictive disorders |
| AU2008213643A1 (en) | 2007-02-08 | 2008-08-14 | Kempharm, Inc. | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
| AU2008226541B2 (en) | 2007-03-09 | 2013-05-09 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia |
| WO2008112773A2 (en) | 2007-03-12 | 2008-09-18 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension |
| US20080226715A1 (en) | 2007-03-16 | 2008-09-18 | Albert Cha | Therapeutic compositions and methods |
| DE102007014286A1 (en) | 2007-03-19 | 2008-09-25 | Universität Tübingen | Fluorine-substituted amphetamines and amphetamine derivatives and their use |
| US10668058B2 (en) | 2007-03-30 | 2020-06-02 | Philip Morris Products S.A. | Device and method for delivery of a medicament |
| AT505086B1 (en) | 2007-04-02 | 2009-06-15 | Planta Naturstoffe Vertriebsge | PHARMACEUTICAL AGENT AGAINST JUCKREIZ AND JUCKREIZED PAIN |
| WO2008122990A1 (en) | 2007-04-04 | 2008-10-16 | Almet Corporation Limited | Compacting upflow extractor and method of using it |
| WO2008128193A1 (en) | 2007-04-12 | 2008-10-23 | Rutgers, The State University Of New Jersey | Biodegradable polyanhydrides with natural bioactive molecules |
| WO2008130678A2 (en) | 2007-04-18 | 2008-10-30 | Teva Pharmaceutical Industries Ltd. | Rosuvastatin intermediates and process for the preparation of rosuvastatin |
| WO2008134525A1 (en) | 2007-04-26 | 2008-11-06 | Auspex Pharmaeuticals, Inc. | Deuterium labelled ketamine |
| US9421266B2 (en) | 2007-05-22 | 2016-08-23 | Pisgah Laboratories, Inc. | Safety of pseudoephedrine drug products |
| US10183001B1 (en) | 2007-05-22 | 2019-01-22 | Pisgah Laboratories, Inc. | Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features |
| MX2010001141A (en) | 2007-07-31 | 2010-03-01 | Limerick Biopharma Inc | Phosphorylated pyrone analogs and methods. |
| PL2185155T3 (en) | 2007-08-03 | 2018-03-30 | Richter Gedeon Nyrt. | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands |
| RU2491067C2 (en) | 2007-08-06 | 2013-08-27 | Байотай Терапис, Инк | Method of treating addiction |
| FR2919861A1 (en) | 2007-08-06 | 2009-02-13 | Sanofi Aventis Sa | RIMONABANT ISOPRANOL SOLVATE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| AU2016208412A1 (en) | 2007-08-06 | 2016-08-18 | Biotie Therapies, Inc. | Methods for treating dependence |
| WO2009019472A1 (en) | 2007-08-07 | 2009-02-12 | Prosarix Limited | 1, 2, 4 -triazole derivatives as serotonergic modulators |
| US8067028B2 (en) | 2007-08-13 | 2011-11-29 | Confluent Surgical Inc. | Drug delivery device |
| US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| JP5599712B2 (en) | 2007-10-05 | 2014-10-01 | インターフェース バイオロジクス，インコーポレーテッド | Oligofluorinated cross-linked polymer and use thereof |
| WO2009049215A1 (en) | 2007-10-10 | 2009-04-16 | Wake Forest University Health Sciences | Methods to reduce the effects of sleep deprivation |
| WO2009055001A2 (en) | 2007-10-23 | 2009-04-30 | Fred Hutchinson Cancer Research Center | Methods of treating aging and methods of screening candidate agents therefor |
| WO2009061436A1 (en) | 2007-11-06 | 2009-05-14 | University Of Florida Research Foundation | Compound for activating 5-ht2c receptors in combination with an amphetamine compound |
| DE102007063210A1 (en) | 2007-12-20 | 2009-06-25 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Medicines for the treatment of phantom phenomena |
| WO2009079765A1 (en) | 2007-12-21 | 2009-07-02 | Cascade Therapeutics Inc. | Compounds with activity at the 5-ht2c receptor |
| US20090176792A1 (en) | 2008-01-07 | 2009-07-09 | Auspex Pharmaceuticals, Inc. | Substituted dibenzhydrylpiperazines |
| WO2009089494A2 (en) | 2008-01-09 | 2009-07-16 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| US8137690B2 (en) | 2008-01-17 | 2012-03-20 | Health Innovations, Llc | Taste titration therapies |
| WO2009097596A1 (en) | 2008-01-31 | 2009-08-06 | Paul Griffin | Compositions and methods for the treatment of chronic infections |
| US8329663B2 (en) | 2008-01-31 | 2012-12-11 | Paul Griffin | Compositions and methods for the treatment of chronic infections |
| MX2010008024A (en) | 2008-02-01 | 2010-12-21 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker. |
| JP6088123B2 (en) | 2008-02-01 | 2017-03-01 | アルファ−オー・ペプチドズ・アーゲーＡｌｐｈａ−Ｏ Ｐｅｐｔｉｄｅｓ Ａｇ | Self-assembling peptide nanoparticles useful as vaccines |
| US20090198145A1 (en) | 2008-02-06 | 2009-08-06 | Chow Harrison | Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep |
| EP2254865A1 (en) | 2008-02-11 | 2010-12-01 | Organix, Inc. | Indole compounds and methods of use thereof |
| US8859579B2 (en) | 2008-03-21 | 2014-10-14 | Richard Andrew Sewell | Compostions and methods for preventing and/or treating disorders associated with cephalic pain |
| WO2009118179A1 (en) | 2008-03-26 | 2009-10-01 | Lonza Ltd | Process for the synthesis of ethynylcyclopropane |
| US20170276676A1 (en) | 2008-03-27 | 2017-09-28 | Gus J. Slotman | System for assessing drug efficacy and response of a patient to therapy |
| WO2009118763A1 (en) | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Multilayered pharmaceutical compositions and processes thereof |
| US20090252786A1 (en) | 2008-03-31 | 2009-10-08 | Christoph Hanz | Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor |
| EP2106799A1 (en) | 2008-03-31 | 2009-10-07 | OWEN Holding LTD | Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a GABA receptor |
| FR2930147B1 (en) | 2008-04-18 | 2013-02-08 | Flamel Tech Sa | SOLID ORAL FORM WITH A DOUBLE RELEASE PROFILE |
| CN102014625A (en) | 2008-04-28 | 2011-04-13 | 佐吉尼克斯股份有限公司 | Novel formulations for treatment of migraine |
| CN102056624A (en) | 2008-06-04 | 2011-05-11 | 康奈尔大学 | Vaccines for prevention and treatment of addiction |
| US10388179B2 (en) | 2008-06-18 | 2019-08-20 | Accenture Global Solutions Limited | Analytics platform |
| EP3308777A1 (en) | 2008-06-19 | 2018-04-18 | LTS Lohmann Therapie-Systeme AG | Composition for transdermal delivery of cationic active agents |
| WO2010001391A1 (en) | 2008-06-30 | 2010-01-07 | Oron Zachar | Dermal application of vasoconstrictors |
| US9642819B2 (en) | 2008-07-10 | 2017-05-09 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical | Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation |
| US8617607B2 (en) | 2008-07-10 | 2013-12-31 | Tyrx, Inc. | Sustained release formulations of psychoactive drugs |
| EP2331088A4 (en) | 2008-08-06 | 2011-10-12 | Gosforth Ct Holdings Pty Ltd | Compositions and methods for treating psychiatric disorders |
| FR2935611B1 (en) | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | USE OF ANTI-CONNEXINE AGENTS FOR MODULATING THE THERAPEUTIC EFFECT OF PSYCHOTROPIC MOLECULES |
| FR2936710B1 (en) | 2008-10-07 | 2011-01-07 | Ceva Sante Animale | ANTIPROLACTINIC VETERINARY COMPOSITION FOR RUMINANTS |
| EP2389187B1 (en) | 2009-01-20 | 2016-11-16 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical |
| UA105657C2 (en) | 2009-02-27 | 2014-06-10 | Хелсінн Терапьютікс (Ю.Ес.), Інк. | Enhanced migraine treatments based on anamorelin |
| WO2010124089A2 (en) | 2009-04-22 | 2010-10-28 | Synosia Therapeutics, Inc. | Methods for treating dependence |
| US20120159656A1 (en) | 2009-04-24 | 2012-06-21 | Galenea Corp. | Compositions and methods for evaluating cognitive defects |
| WO2010136803A1 (en) | 2009-05-26 | 2010-12-02 | Shire Llc | Methods of enhancing selective serotonin reuptake inhibitor effects in mammals |
| GB201111485D0 (en) | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
| US20110306596A1 (en) | 2009-07-27 | 2011-12-15 | Auspex Pharmaceuticals, Inc. | Benzazepine inhibitors of gamma-secretase |
| US20120302590A1 (en) | 2009-08-13 | 2012-11-29 | The General Hospital Corporation | Methods and compositions to prevent addiction |
| US20110038915A1 (en) | 2009-08-14 | 2011-02-17 | Eduardo Jose Gonzalez | Chewing Gum Formula for Enhancing Psycho-Spirituality |
| US20120171239A1 (en) | 2009-09-03 | 2012-07-05 | Mizel Steven B | Immunogenic Conjugates for Producing Immune Responses to Drugs of Abuse and Methods of Use |
| FR2954167A1 (en) | 2009-09-04 | 2011-06-24 | Centre Nat Rech Scient | OCYTOCINE TREATMENT OF BEHAVIORAL CHARACTERISTICS ASSOCIATED WITH AUTISM AND PATHOLOGICAL TIMIDITY |
| FR2951378B1 (en) | 2009-10-16 | 2012-06-01 | Flamel Tech Sa | ANTI-MEASURING SOLID ORAL PHARMACEUTICAL FORM WITH A SPECIFIC MODIFIED RELEASE PROFILE |
| WO2011045443A1 (en) | 2009-10-16 | 2011-04-21 | Dsm Ip Assets B.V. | Coatings comprising bis-(alpha-amino-diol-diester) containing polyesteramide |
| EP2490677A2 (en) | 2009-10-19 | 2012-08-29 | Intec Pharma Ltd. | Novel gastroretentive dosage forms of poorly soluble drugs |
| EP2513225A4 (en) | 2009-12-18 | 2015-08-12 | Interface Biologics Inc | Local delivery of drugs from self assembled coatings |
| EP2531200B1 (en) | 2010-02-06 | 2017-07-12 | Grünenthal GmbH | Crystallization method and bioavailability |
| US20110217289A1 (en) | 2010-03-05 | 2011-09-08 | Basf Se | Melt-Coated Dosage Forms |
| WO2011109809A2 (en) | 2010-03-05 | 2011-09-09 | New Agriculture, Inc | A novel composition of matter for delivering lipid-soluble materials, and a method for producing it |
| CN102892429B (en) | 2010-03-17 | 2016-08-31 | 康奈尔大学 | Abuse resistant drugs vaccine based on destroyed adenovirus |
| WO2011138142A1 (en) | 2010-05-07 | 2011-11-10 | Ecole Polytechnique Federale De Lausanne (Epfl) | Compositions and use of sulfasalazine |
| CA2792018A1 (en) | 2010-05-10 | 2011-11-17 | Segetis, Inc. | Fragrant formulations, methods of manufacture thereof and articles comprising the same |
| US8765737B1 (en) | 2010-05-11 | 2014-07-01 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
| US8362007B1 (en) | 2010-05-11 | 2013-01-29 | Demerx, Inc. | Substituted noribogaine |
| US20120108510A1 (en) | 2010-05-20 | 2012-05-03 | Emory University | Methods of improving behavioral therapies |
| JP2012020991A (en) | 2010-06-16 | 2012-02-02 | Takasago Internatl Corp | Transdermal absorption promoter, and external skin formulation thereof |
| US8802832B2 (en) | 2010-06-22 | 2014-08-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| CA2806232A1 (en) | 2010-07-23 | 2012-01-26 | Demerx, Inc. | Noribogaine compositions |
| EP3333185A1 (en) | 2010-08-20 | 2018-06-13 | Heptares Therapeutics Limited | Mutant gpcrs |
| EP2611466B1 (en) | 2010-08-30 | 2019-06-12 | President and Fellows of Harvard College | Shear controlled release of thrombolytic therapies for stenotic lesions |
| US20130310422A1 (en) | 2010-09-01 | 2013-11-21 | The General Hospital Corporation | Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine |
| US20120129834A1 (en) | 2010-09-17 | 2012-05-24 | Buck Institute For Research On Aging | Serotonin receptor antagonists for use in the treatment of huntington's disease |
| EP2618826B1 (en) | 2010-09-20 | 2016-04-13 | A.Carlsson Research AB | Phenylpiperidine compounds for the treatment of dementia |
| WO2012045118A1 (en) | 2010-10-07 | 2012-04-12 | Eaglepharma Pty Ltd | Combination therapy for the treatment of depression and other non-infectious diseases |
| EP2629615B1 (en) | 2010-10-22 | 2018-10-10 | Duke University | Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies |
| US20130230587A1 (en) | 2010-11-10 | 2013-09-05 | Rubicon Research Private Limited | Sustained release compositions |
| WO2012066537A2 (en) | 2010-11-15 | 2012-05-24 | Neuroderm Ltd | Compositions for transdermal delivery of active agents |
| EP2649443A2 (en) | 2010-12-06 | 2013-10-16 | Ramot at Tel-Aviv University Ltd | Methods and kits for detection of drugs |
| PL2654864T3 (en) | 2010-12-22 | 2021-07-12 | Syqe Medical Ltd. | System for drug delivery |
| EP2481740B1 (en) | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
| FR2971423B1 (en) | 2011-02-15 | 2014-01-10 | Ceva Sante Animale | ANTIPROLACTINIC VETERINARY COMPOSITION FOR RUMINANTS |
| US8742096B2 (en) | 2011-03-28 | 2014-06-03 | Demerx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
| CN103502817B (en) | 2011-03-28 | 2016-01-20 | 前视红外***股份有限公司 | Comprise the detection method of the analysis thing of medicine |
| JOP20120083B1 (en) | 2011-04-05 | 2021-08-17 | Otsuka Pharma Co Ltd | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
| US20120282255A1 (en) | 2011-04-07 | 2012-11-08 | Greg Plucinski | Methods and compositions for the treatment of alcoholism and alcohol dependence |
| KR20120128440A (en) | 2011-05-17 | 2012-11-27 | 삼성전자주식회사 | Kit and method for detecting target material |
| US9089563B2 (en) | 2011-05-19 | 2015-07-28 | Gilrose Pharmaceuticals, Llc | Method of treating apraxia of speech in children |
| US20140163070A1 (en) | 2012-05-17 | 2014-06-12 | Bruce Roseman | Treatment for cerebral palsy impaired speech in children |
| WO2012177962A1 (en) | 2011-06-23 | 2012-12-27 | Map Pharmaceuticals, Inc. | Novel fluoroergoline analogs |
| AU2012308274B2 (en) | 2011-09-15 | 2017-08-17 | Demerx, Inc. | Noribogaine salt ansolvates |
| US20130116215A1 (en) | 2011-10-28 | 2013-05-09 | Mireia Coma | Combination therapies for treating neurological disorders |
| MX354924B (en) | 2011-11-07 | 2018-03-22 | Novartis Ag | Carrier molecule comprising a spr0096 and a spr2021 antigen. |
| FR2983409B1 (en) | 2011-12-06 | 2013-12-27 | Ethypharm Sa | COMPRESSOR CAPABLE OF COMBATTING INJECTION MISTAKE |
| CA3122767C (en) | 2011-12-08 | 2023-03-28 | Demerx, Inc. | Stereoselective total synthesis of noribogaine |
| CA2855990A1 (en) | 2011-12-09 | 2013-06-13 | Demerx, Inc. | Sulfate esters of noribogaine |
| JP2015500833A (en) | 2011-12-09 | 2015-01-08 | デメレックス， インコーポレイテッド | Nolibogaine phosphate |
| EP2607352A1 (en) | 2011-12-22 | 2013-06-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pipecolate-diketoamides for treatment of psychiatric disorders |
| EP2610245A1 (en) | 2011-12-28 | 2013-07-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pipecolate-sulfonamides for treatment of psychiatric disorders |
| WO2013112163A1 (en) | 2012-01-25 | 2013-08-01 | Demerx, Inc. | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
| CA2858820C (en) | 2012-01-25 | 2021-08-17 | Demerx, Inc. | Synthetic voacangine |
| EP2807167A4 (en) | 2012-01-25 | 2016-01-20 | Demerx Inc | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
| EP2649989B1 (en) | 2012-04-13 | 2017-10-18 | King Saud University | Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof |
| US20130295170A1 (en) | 2012-05-03 | 2013-11-07 | Kydes Pharmaceuticals Llc | Compositions for control of drug abuse |
| US20130295016A1 (en) | 2012-05-07 | 2013-11-07 | David J. Gerber | Signatures of electroencephalographic oscillations |
| KR102452803B1 (en) | 2012-05-09 | 2022-10-07 | 캔텍스 파마슈티칼즈, 인크. | Treatment of myelosuppression |
| US8784835B2 (en) | 2012-07-02 | 2014-07-22 | Trent Austin | Method for producing muscimol and/or reducing ibotenic acid from amanita tissue |
| WO2014008118A2 (en) | 2012-07-02 | 2014-01-09 | The General Hospital Corporation | Method for concurrent treatment of pain and depression |
| EP2690102A1 (en) | 2012-07-24 | 2014-01-29 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bicyclic aza-amides for treatment of psychiatric disorders |
| CA2878624C (en) | 2012-08-17 | 2021-03-02 | Smartek International Llc | Preparation of desiccated liposomes for use in compressible delivery systems |
| CA2882870C (en) | 2012-08-24 | 2020-12-15 | Integurx Therapeutics, Llc | Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents |
| US20140066881A1 (en) | 2012-08-31 | 2014-03-06 | Zoll Medical Corporation | Cardiac resuscitation methods and kits |
| US20140100282A1 (en) | 2012-10-10 | 2014-04-10 | Patrick S L Wong | Intranasal administration of pharmaceutical agents for treatment of neurological diseases |
| US20150231300A1 (en) | 2012-10-28 | 2015-08-20 | Peritech Pharma Ltd. | Pharmaceutical liquid adhesive compositions for treatment of anorectal disorders |
| WO2014078857A1 (en) | 2012-11-19 | 2014-05-22 | Regents Of The University Of Minnesota | Ergoline derivatives as dopamine receptor modulators |
| WO2014093277A1 (en) | 2012-12-11 | 2014-06-19 | The Mclean Hospital Corporation | Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders |
| EP2934541A4 (en) | 2012-12-20 | 2016-08-03 | Demerx Inc | Substituted noribogaine |
| EP3485882A1 (en) | 2013-01-25 | 2019-05-22 | Case Western Reserve University | Compositions for the treatment of pervasive development disorders |
| WO2014130581A1 (en) | 2013-02-20 | 2014-08-28 | Questcor Pharmaceuticals, Inc. | Acth for treatment of migraine headache |
| US20140255522A1 (en) | 2013-03-10 | 2014-09-11 | Peritech Pharma Ltd. | Topical compositions and methods of treatment of anorectal and genital disorders |
| US20140288454A1 (en) | 2013-03-14 | 2014-09-25 | Pulmonary Analytics | Method For Using Exhaled Breath to Determine the Presence of Drug |
| WO2014142938A1 (en) | 2013-03-15 | 2014-09-18 | Aihol Corporation | Pharmaceutical formulation containing glycosaminoglycan |
| WO2014143201A1 (en) | 2013-03-15 | 2014-09-18 | Demerx, Inc. | Method for noribogaine treatment of addiction in patients on methadone |
| US20160030408A1 (en) | 2013-03-15 | 2016-02-04 | Bhl Patent Holdings Llc | Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve |
| CA2904539C (en) | 2013-03-15 | 2022-05-03 | Melior Discovery, Inc. | Methods of treating dyskinesia and related disorders |
| US20160077091A1 (en) | 2013-04-26 | 2016-03-17 | Express Diagnostics International, Inc. | Portable testing system for detecting selected drugs or compounds in noncontrolled environments |
| WO2014186623A2 (en) | 2013-05-17 | 2014-11-20 | Biomed Valley Discoveries | Methods and compositions for the treatment of a chagas disease |
| AR096438A1 (en) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | DOSAGE FORM RESISTANT TO INDEBITED USE WITH BIMODAL RELEASE PROFILE, PROCESS |
| CA2817728A1 (en) | 2013-05-31 | 2014-11-30 | Pharmascience Inc. | Abuse deterrent immediate release formulation |
| EA201592236A1 (en) | 2013-06-04 | 2016-06-30 | Вайом Байосайнсиз Пвт. Лтд. | PARTICULATED COATINGS AND COMPOSITIONS INCLUDING SUCH PARTICLES |
| WO2014197753A1 (en) | 2013-06-08 | 2014-12-11 | Sedogen, Llc | Method of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia |
| EP2818177A1 (en) | 2013-06-24 | 2014-12-31 | Celica, D.O.O. | Mechanism and drug targets for reducing cell edema (neuroprotection) and cytoplasmic excitability in astrocytes in normal and pathological states |
| EP3016645A4 (en) | 2013-07-03 | 2016-12-21 | Acura Pharmaceuticals Inc | Methods and compositions for deterring abuse |
| PE20160556A1 (en) | 2013-07-08 | 2016-06-11 | Auspex Pharmaceuticals Inc | DIHYDROXYPHENYL NEUROTRANSMITTER COMPOUNDS, COMPOSITIONS AND METHODS |
| AU2014289187B2 (en) | 2013-07-12 | 2019-07-11 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| US9770514B2 (en) | 2013-09-03 | 2017-09-26 | ExxPharma Therapeutics LLC | Tamper-resistant pharmaceutical dosage forms |
| US10098893B2 (en) | 2013-10-03 | 2018-10-16 | Northwestern University | Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457 |
| US9420970B2 (en) | 2013-10-22 | 2016-08-23 | Mindstrong, LLC | Method and system for assessment of cognitive function based on mobile device usage |
| US9474481B2 (en) | 2013-10-22 | 2016-10-25 | Mindstrong, LLC | Method and system for assessment of cognitive function based on electronic device usage |
| WO2015065546A2 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Abuse-deterrent dosage forms |
| WO2015065547A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| TW201605856A (en) | 2013-11-01 | 2016-02-16 | 艾尼納製藥公司 | 5-HT2c receptor agonists |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| CN103535561A (en) | 2013-11-05 | 2014-01-29 | 杨剑 | Forage feed for raising big pigs |
| CN103549133A (en) | 2013-11-05 | 2014-02-05 | 杨剑 | Organic forage feed for pigs |
| CN103751943B (en) | 2014-01-13 | 2020-10-13 | 湖北及安盾消防科技有限公司 | Fire extinguishing composition containing nitrogen-containing organic compound |
| AU2014379612A1 (en) | 2014-01-24 | 2016-08-11 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| CN103773056B (en) | 2014-01-24 | 2015-11-18 | 山东大学 | High brittle transparent rock-like materials test material preparation method |
| CA3212001A1 (en) | 2014-03-03 | 2015-09-11 | Demerx, Inc. | Therapeutic uses of ibogaine and related compounds |
| US20150258114A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods for acute and long-term treatment of substance abuse using ibogaine |
| WO2015187289A1 (en) | 2014-06-03 | 2015-12-10 | Pop Test Abuse Deterrent Technology Llc | Drug device configured for wireless communication |
| MX2017001279A (en) | 2014-07-30 | 2017-08-07 | Cleveland Biolabs Inc | Flagellin compositons and uses. |
| US10231651B2 (en) | 2014-09-25 | 2019-03-19 | Bae Systems Information And Electronic Systems Integration Inc. | Gait authentication system and method thereof |
| US10058253B2 (en) | 2014-11-11 | 2018-08-28 | Zenmark, Llc | System, method, and article for heart rate variability monitoring |
| WO2016145193A1 (en) | 2015-03-10 | 2016-09-15 | Eleusis Benefit Corporation, Pbc | Lsd for the treatment of alzheimer's disease |
| KR20170130531A (en) | 2015-03-24 | 2017-11-28 | 교와 핫꼬 기린 가부시키가이샤 | The nucleic acid-containing lipid nanoparticles |
| US10254298B1 (en) | 2015-03-25 | 2019-04-09 | National Technology & Engineering Solutions Of Sandia, Llc | Detection of metabolites for controlled substances |
| WO2016161138A1 (en) * | 2015-03-31 | 2016-10-06 | Stamets Paul Edward | Antiviral activity from medicinal mushrooms and their active constituents |
| WO2016176177A1 (en) | 2015-04-27 | 2016-11-03 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| CN107073293A (en) | 2015-05-01 | 2017-08-18 | 托匹泰克以色列制药有限公司 | Composition for treating nosebleed |
| US20180147142A1 (en) | 2015-05-19 | 2018-05-31 | Joseph Robert Knight | Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids |
| CA2968703A1 (en) | 2015-05-19 | 2016-11-24 | Joseph Robert Knight | Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids |
| US9737759B2 (en) | 2015-07-17 | 2017-08-22 | Genesant Technologies, Inc. | Automatic application-based exercise tracking system and method |
| CN108137508B (en) | 2015-07-31 | 2021-08-27 | 艾尼纳制药公司 | 5-HT2CReceptor agonists and compositions and methods of use |
| US9614734B1 (en) | 2015-09-10 | 2017-04-04 | Pearson Education, Inc. | Mobile device session analyzer |
| US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| JP6977024B2 (en) | 2016-08-19 | 2021-12-08 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 5-HT2C Receptor Agonists and Compositions and Methods of Use |
| US10596378B2 (en) | 2016-10-18 | 2020-03-24 | Joseph Rustick | Method for treatment of depression using synaptic pathway training |
| US20180195455A1 (en) | 2017-01-12 | 2018-07-12 | GM Global Technology Operations LLC | Engine combustion phasing control during transient state |
| NL2018190B1 (en) | 2017-01-18 | 2018-07-26 | Procare Beheer B V | Psilocybin or psilocin in combination with cannabinoid |
| CA3051914A1 (en) | 2017-02-02 | 2018-08-09 | Mcmaster University | Bicarbonate as a potentiator for antimicrobial agents |
| AU2018217829A1 (en) * | 2017-02-09 | 2019-09-12 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| US20190142851A1 (en) | 2017-11-16 | 2019-05-16 | CaaMTech, LLC | Compositions comprising a psilocybin derivative and a cannabinoid |
| WO2018145219A1 (en) | 2017-02-09 | 2018-08-16 | Serani Mostazal Jorge | Pharmaceutical composition for preventing and treating addictions by means of aversive counterconditioning |
| CN108619214A (en) | 2017-03-15 | 2018-10-09 | 王慎君 | A kind of drug for treating tumour |
| BR112019020554A2 (en) | 2017-03-30 | 2020-04-28 | Ojai Energetics Pbc | methods and compositions to improve health conditions |
| US11498922B2 (en) | 2017-04-07 | 2022-11-15 | ACEA Therapeutics, Inc. | Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide |
| US20200147038A1 (en) | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| US20180343812A1 (en) | 2017-05-31 | 2018-12-06 | Insectergy, Llc | Cannabis farming systems and methods |
| US20190246591A1 (en) | 2017-05-31 | 2019-08-15 | Insectergy, Llc | Insect and cannabis production systems and methods |
| JP2020522693A (en) | 2017-06-02 | 2020-07-30 | ノースウェスタン ユニヴァーシティＮｏｒｔｈｗｅｓｔｅｒｎ Ｕｎｉｖｅｒｓｉｔｙ | Thin flexible skin-worn microfluidic network for detection and analysis of focused targets in sweat |
| CN107252080A (en) | 2017-07-12 | 2017-10-17 | 沈建国 | A kind of formula of numb mushroom sauce |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| EP3698260A4 (en) | 2017-10-19 | 2021-08-04 | Eleusis Health Solutions US, Inc. | Methods and systems for enhancing safety of psychedelic drug therapies |
| WO2019081764A1 (en) | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | Combination product for the treatment of neurological and/or psychiatric disorders |
| US10703325B2 (en) | 2017-11-27 | 2020-07-07 | Autoliv Asp, Inc. | Multi-chambered side airbag assemblies |
| EP3720506A4 (en) | 2017-12-04 | 2021-09-29 | Lecouteur, David | Compositions and methods for modulating liver endothelial cell fenestrations |
| FI128750B (en) | 2017-12-21 | 2020-11-30 | Helsingin Yliopisto | Methods for determining the therapeutic efficacy of rapid-acting antidepressants and personalized antidepressant therapy related thereto |
| WO2019144140A1 (en) | 2018-01-22 | 2019-07-25 | CyPhi LLC | Bio-mimetic formulation |
| WO2019161050A1 (en) | 2018-02-18 | 2019-08-22 | Akili Interactive Labs, Inc. | Cognitive platform including computerized elements coupled with a therapy for mood disorder |
| CA3093301A1 (en) | 2018-03-08 | 2019-09-12 | New Atlas Biotechnologies Llc | Processes for the production of tryptamines |
| FI129102B (en) | 2018-03-19 | 2021-07-15 | Teknologian Tutkimuskeskus Vtt Oy | Heterologous production of psilocybin |
| MX2020011653A (en) | 2018-05-04 | 2021-02-09 | Perception Neuroscience Inc | Methods of treating substance abuse. |
| CA3148256A1 (en) | 2018-06-21 | 2019-12-26 | Robert John Petcavich | Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases |
| WO2020024060A1 (en) | 2018-08-01 | 2020-02-06 | Mcmaster University | Methods for inhibiting microbe growth |
| US20210251969A1 (en) | 2018-08-20 | 2021-08-19 | Yale University | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases |
| WO2020053196A1 (en) | 2018-09-10 | 2020-03-19 | Universität Basel | Method for the biocatalytic alkylation of a substrate |
| AU2019419450A1 (en) | 2019-01-04 | 2021-07-22 | Apollo Neuroscience, Inc. | Systems and methods of wave generation for transcutaneous vibration |
| AU2020215150A1 (en) | 2019-01-30 | 2021-09-09 | Diamond Therapeutics Inc | Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders |
| JP2022529781A (en) | 2019-04-17 | 2022-06-24 | コンパス パスファインダー リミテッド | Treatment of depression and various other disorders with psilocybin |
| US11766445B2 (en) | 2019-07-18 | 2023-09-26 | Concept Matrix Solutions | Oral soft gel capsule containing psychedelic compound |
| EP4009026A1 (en) | 2020-12-02 | 2022-06-08 | Volvo Truck Corporation | An air-actuated vehicle system and a method of detecting leakage in an air-actuated vehicle system |
| TW202304466A (en) | 2021-03-30 | 2023-02-01 | 英商康派斯開拓者公司 | Psilocybin compositions, methods of making and methods of using the same |
-
2020
- 2020-04-17 JP JP2021561958A patent/JP2022529781A/en active Pending
- 2020-04-17 JP JP2021561957A patent/JP2022529353A/en active Pending
- 2020-04-17 CN CN202080042624.3A patent/CN114206349A/en active Pending
- 2020-04-17 AU AU2020258086A patent/AU2020258086A1/en active Pending
- 2020-04-17 EP EP20721772.0A patent/EP3955918A1/en active Pending
- 2020-04-17 WO PCT/IB2020/053688 patent/WO2020212952A1/en unknown
- 2020-04-17 US US17/604,619 patent/US20230000883A1/en active Pending
- 2020-04-17 CA CA3138094A patent/CA3138094A1/en active Pending
- 2020-04-17 CN CN202080044103.1A patent/CN113993523A/en active Pending
- 2020-04-17 CN CN202080043682.8A patent/CN113993522A/en active Pending
- 2020-04-17 KR KR1020217037273A patent/KR20220009955A/en unknown
- 2020-04-17 WO PCT/IB2020/053687 patent/WO2020212951A1/en unknown
- 2020-04-17 US US17/604,606 patent/US20220169668A1/en active Pending
- 2020-04-17 TW TW109113103A patent/TW202103699A/en unknown
- 2020-04-17 EP EP20721775.3A patent/EP3955919A1/en active Pending
- 2020-04-17 EP EP20721776.1A patent/EP3955936A1/en active Pending
- 2020-04-17 CA CA3138008A patent/CA3138008A1/en active Pending
- 2020-04-17 CA CA3138100A patent/CA3138100A1/en active Pending
- 2020-04-17 AU AU2020259406A patent/AU2020259406A1/en active Pending
- 2020-04-17 US US17/604,610 patent/US20230023092A1/en active Pending
- 2020-04-17 WO PCT/IB2020/053684 patent/WO2020212948A1/en unknown
- 2020-04-17 AU AU2020257625A patent/AU2020257625A1/en active Pending
- 2020-04-17 KR KR1020217037272A patent/KR20220009954A/en active Search and Examination
- 2020-04-17 KR KR1020217037271A patent/KR20220008824A/en unknown
- 2020-04-17 JP JP2021561959A patent/JP2022529476A/en active Pending
-
2021
- 2021-12-02 US US17/540,962 patent/US11564935B2/en active Active
-
2022
- 2022-12-08 US US18/077,876 patent/US11738035B2/en active Active
-
2023
- 2023-06-15 US US18/210,526 patent/US11865126B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020212952A5 (en) | ||
| KR101067045B1 (en) | Treatment of CNS disorders with trans 4-3,4-dichlorophenyl-1,2,3,4-tetrahydro-1-naphthalenamine | |
| JP4180365B2 (en) | Piperazine derivatives | |
| CN115135320B (en) | Specific tryptamine for the treatment of mood disorders | |
| KR20230142817A (en) | Compounds | |
| RU2661156C2 (en) | Substituted naphthyridine and quinoline compounds as mao inhibitors | |
| WO2005040135A1 (en) | Antistress drug and medical use thereof | |
| JP6810613B2 (en) | Organic compounds | |
| RU2015101647A (en) | CRYSTALS OF SALT | |
| KR20200096596A (en) | Deuterated 21-[4-cyano-pyrazole-1-yl]-19-nor-pregan-3 for the treatment of CNS disorders. Alpha-ol-20-one derivative | |
| TW201011033A (en) | Prodrugs of fused heterocyclic inhibitors of D-amino acid oxidase | |
| JP2020023496A6 (en) | Organic compound | |
| JP5538542B2 (en) | Carbocyclic GlyT1 receptor antagonist | |
| NO321674B1 (en) | Use of N-desmethylzopiclones and pharmaceutical composition | |
| WO2015200619A1 (en) | Inhibitors of histone deacetylase | |
| TW202220965A (en) | 2-aminoindane compounds for mental disorders or enhancement | |
| CA3144701A1 (en) | Compositions and methods for treating cns disorders | |
| TW200810752A (en) | Modulators of muscarinic receptors | |
| JP6321274B2 (en) | Triple reuptake inhibitors and methods of their use | |
| US20060019992A1 (en) | Cycloalkylamine derivatives as NK-1/SSRI antagonists | |
| EP3490607A1 (en) | Compounds and compositions and uses thereof | |
| AU2002356903A2 (en) | Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram | |
| JP5573677B2 (en) | 2,3-Dihydro-1H-inden-2-ylurea derivative and pharmaceutical use thereof | |
| US9381170B2 (en) | Cycloalkyl-diamines for neurodegenerative disorders | |
| JP4914346B2 (en) | Benzoxazolone derivatives, methods for their preparation and uses thereof |